



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>C07K 14/54</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 00/23471</b> <b>(43) International Publication Date:</b> 27 April 2000 (27.04.00)
<b>(21) International Application Number:</b> PCT/EP99/07800 <b>(22) International Filing Date:</b> 6 October 1999 (06.10.99) <b>(30) Priority Data:</b> 98203529.7      20 October 1998 (20.10.98)      EP <b>(71) Applicant (for all designated States except US):</b> VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR BIOTECH- NOLOGIE VZW [BE/BE]; Rijvisschestraat 120, B-9052 Zwijnaarde (BE). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> STEIDLER, Lothar [BE/BE]; Bokslaarstraat 41, B-9160 Lokeren (BE). REMAUT, Erik, Rene [BE/BE]; Bergstraat 7, B-9921 Vinderhout (BE). FIERS, Walter [BE/BE]; Beukendreef 3, B-9070 Destelbergen (BE). <b>(74) Common Representative:</b> VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR BIOTECHNOLOGIE VZW; Rijviss- chestraat 120, B-9052 Zwijnaarde (BE).		<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>Without international search report and to be republished          upon receipt of that report.</i>
<b>(54) Title:</b> USE OF A CYTOKINE-PRODUCING <i>LACTOCOCCUS</i> STRAIN TO TREAT COLITIS		
<b>(57) Abstract</b> <p>The current invention relates to an administraton strategy for the delivery at the intestinal mucosa of cytokines or cytokine antagonists, preferably of acid sensitive anti-inflammatory agents, such as IL10 and/or soluble TNF receptor via the oral route. The prepered feature according to the invention is the inoculation with a suspension of recombinant <i>Lactococcus lactis</i> cells, which had been engineered to produce the respective proteins.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

**Use of a cytokine-producing *Lactococcus* strain to treat colitis.**

5

Summary of the invention

The invention generally relates to an administration strategy for the delivery at the intestinal mucosa of cytokines, preferably of acid sensitive anti-inflammatory agents, such as IL10 and/or a soluble TNF receptor via the oral route. The preferred feature according to the invention is the inoculation with a suspension of live recombinant *Lactococcus lactis* cells, which had been engineered to produce the respective proteins. As example, mice were used in which a chronic inflammation of the distal colon had been induced by administration with dextran sulfate sodium (DSS). The treatment as scored by histological evaluation clearly resulted in a regression of the inflammation and disease symptoms. The finding is highly unexpected since, in order to exert activity at the colon following oral administration, the delivery system needs to pass the acidic environment of the stomach and the upper part of the small intestine respectively.

20

Background to the invention

The immune system in a mammal is diverse and complex and includes natural and adaptive immune mechanisms and reactions. The immune system is often described in terms of either humoral or cellular immune responses. Humoral immunity refers broadly to antibody production and actions by B-cells; cellular immunity is mediated by cells including T-cells, dendritic cells, neutrophils, monocytes and macrophages. T-cells and B-cells are two categories of lymphocytes.

One of the mechanisms by which the immune system normally acts and regulates itself includes the production of so-called cytokines. It is known that cytokines mediate several positive and negative immune responses. Cytokines normally act by binding to a receptor on a target cell. The activity of cytokines

can be interfered with in several ways, for example by administration of soluble receptors ( extracellular domains of the receptor ) or by cytokine analogues or derivatives.

IL-10 is a cytokine capable of mediating a number of actions or effects. It is  
5 known that IL-10 is involved in controlling the immune responses of different classes or subsets of Th cells (T-helper cells).

Inflammatory bowel disease (IBD) refers to a group of gastrointestinal disorders characterized by a chronic non-specific inflammation of portions of the gastrointestinal tract. Ulcerative colitis (UC) and Crohn's Disease (CD) are the  
10 most prominent examples of IBD in humans. They are associated with many symptoms and complications, including growth retardation in children, rectal prolapse, blood in stools (e.g., melena and/or hematochezia), wasting, iron deficiency, and anemia, e.g. iron deficiency anemia and anemia of chronic disease or of chronic inflammation. The etiology or etiologies of IBD are  
15 unclear. Reference hereto is made in Wyngaarden and Smith (eds.) *Cecil's Textbook of Medicine* (W.B. Saunders Co. 1985), Berkow (ed.) *The Merck Manual of Diagnosis and Therapy* (Merck Sharp & Dohme Research Laboratories, 1982), and *Harrison's Principles of Internal Medicine*, 12<sup>th</sup> Ed., McGraw-Hill, Inc. (1991).

20 The incidence of IBD varies greatly with geographic location. A collaborative study over Europe shows an incidence per 100 000 of 10,4 for UC and of 5,6 for CD with 40% respectively 80% higher incidence for UC and CD in northern centres when compared to those in the south. As both UC and CD are long time affections, they correspond to real disturbances in the quality of life.  
25 Crohn's disease has a bimodal age distribution of onset showing striking peaks in incidence at 20 and 50 years of age. A higher incidence and more grievous disease profile is associated with the peak at younger age. This makes CD especially poignant as afflicted adolescents and young adults are virtually deprived from the high expectations from life, so particularly associated with  
30 this social group.

Ulcerative colitis refers to a chronic, non-specific, inflammatory, and ulcerative disease having manifestations primarily in the colonic mucosa. It is frequently

characterized by bloody diarrhea, abdominal cramps, blood and mucus in the stools, malaise, fever, anemia, anorexia, weight loss, leukocytosis, hypoalbuminemia, and an elevated erythrocyte sedimentation rate (ESR).

Complications can include hemorrhage, toxic colitis, toxic megacolon, occasional rectovaginal fistulas, and an increased risk for the development of colon cancer.

Ulcerative colitis is also associated with complications distant from the colon, such as arthritis, ankylosing spondylitis, sacroileitis, posterior uveitis, erythema nodosum, pyoderma gangrenosum, and episcleritis.

Treatment varies considerably with the severity and duration of the disease. For instance, fluid therapy to prevent dehydration and electrolyte imbalance is frequently indicated in a severe attack. Additionally, special dietary measures are sometimes useful. Medications include various corticosteroids, sulphasalazine and some of its derivatives, and possibly immunosuppressive drugs.

Crohn's Disease shares many features in common with ulcerative colitis. Crohn's Disease is distinguishable in that lesions tend to be sharply demarcated from adjacent normal bowel, in contrast to the lesions of ulcerative colitis which are fairly diffuse. Additionally, Crohn's Disease predominately afflicts the ileum (ileitis) and the ileum and colon (ileocolitis). In some cases, the colon alone is diseased (granulomatous colitis) and sometimes the entire small bowel is involved (jejunoileitis). In rare cases, the stomach, duodenum, or esophagus are involved. Lesions include a sarcoid-type epithelioid granuloma in roughly half of the clinical cases. Lesions of Crohn's Disease can be transmural including deep ulceration, edema, and fibrosis, which can lead to obstruction and fistula formation as well as abscess formation. This contrasts with ulcerative colitis which usually yields much shallower lesions, although occasionally the complications of fibrosis, obstruction, fistula formation, and abscesses are seen in ulcerative colitis as well.

Treatment is similar for both diseases and includes steroids, sulphasalazine and its derivatives, and immunosuppressive drugs such as cyclosporin A,

mercaptopurine and azathioprine. More recently developed treatments, some still in clinical trials, involve systemic administration ( by injection ) of TNF blocking compounds such as TNF-antibodies or soluble TNF receptor.

- 5 IBD represents a genuine problem in public health because of the absence of etiologic treatment. Although many patients are managed successfully with conventional medical therapy, such as anti-inflammatory corticosteroid treatment, most will have recurrent activity of disease and two-thirds will require surgery.
- 10 The cause of inflammatory bowel diseases is unknown. The pathogenesis of CD and UC probably involves interaction between genetic and environmental factors, such as bacterial agents, although no definite etiological agent has been identified so far. The main theory is that abnormal immune response, possibly driven by intestinal microflora, occurs in IBD. However, what is well
- 15 established is that T-cells play an important role in the pathogenesis. Activated T-cells can produce both anti-inflammatory and pro-inflammatory cytokines. With this knowledge in hand, IBD can be counteracted in a rational manner. Novel anti-inflammatory therapies, which make use of neutralising monoclonal antibodies or anti-inflammatory cytokines, show the possibility to modulate the
- 20 immune disregulations causative to IBD. A highly prominent and effective new therapy is systemic treatment with anti-TNF monoclonal antibodies as mentioned above. Single intravenous doses, ranging from 5 to 20 mg.kg<sup>-1</sup>, of the cA2 infliximab antibody resulted in a drastic clinical improvement in active Crohn's disease. The use of systemically administered recombinant IL-10 in a 7
- 25 day by day treatment regime using doses ranging from 0.5 to 25 µg.kg<sup>-1</sup> showed reduced Crohn's disease activity scores and increased remission. A number of very promising therapies, either tangling pro-inflammatory cytokines or the establishment of T cell infiltrates, are currently emerging from experimental models. All these strategies however require systemic
- 30 administration. The severe complications of IBD can be seriously debilitating, and eventually may lead to death.

Detailed description of the invention

In US Patent 5,368,854, assigned to Schering Corp., a method is disclosed using IL-10 to treat inflammatory bowel diseases in mammals. In this method the cytokine is administered to a mammal having an IBD (inflammatory bowel disease). The administration of IL-10 as described in this reference is  
5 parenteral such as intravascular and preferably intravenous.

It is obvious however that such a route of administration for a (human) patient suffering from an IBD is not without drawbacks. A much easier and more convenient way is an oral administration of a medicament comprising a cytokine such as IL-10 or a cytokine-antagonist which has a similar therapeutic activity.  
10 More importantly, localized release of the therapeutic agent allows for higher efficacy and less unwanted side effects due to systemic activities.

In WO 97/14806, assigned to Cambridge University Technical Services Ltd., a method is disclosed for delivering biologically active polypeptides and/or antigens by using non-invasive bacteria, such as *Lactococcus*, by intranasal  
15 administration of said polypeptides in the body, especially at the mucosa.

However to treat an inflammatory bowel disease such as chronic colitis or Crohn's disease with a cytokine like IL-10, which is acid sensitive, is a very delicate and difficult task to accomplish. Therefore a system needs to be developed wherein the active compound (e.g. a cytokine or a soluble receptor)  
20 is delivered directly at the place where the compound is expected to exert its activity taken into account the problem of acid sensitivity of many cytokines, in particular of IL-10, and the requirement that after oral administration the delivery vehicle needs to pass the acidic environment of the stomach. Furthermore, various digestive enzymes degrade polypeptides as they pass  
25 through the stomach and the gut. Last but not least in-situ administration of the agent may allow to reach therapeutically effective concentrations which are difficult to achieve by more systemic routes of administration because of systemic toxicity or other limitations.

In order to achieve the recovery of a patient suffering from an IBD, it is  
30 necessary to restore the damaged cells and the organ comprising said damaged cells, for instance the colon.

The solution to the above described technical problem is achieved by providing the embodiments characterised in the claims.

5 It is our invention to use a cytokine-producing Gram-positive bacterial strain or a cytokine antagonist producing Gram-positive bacterial strain for the preparation of a medicament to treat inflammatory bowel disease.

Said cytokine or cytokine antagonist to be produced by the bacterial host strain is, for instance, IL-10, a soluble TNF receptor or a cytokine analogue such as  
10 the IL-12 derived p40 homodimer (an IL-12 antagonist), an Interferon- $\gamma$  antagonist, an IL-1 antagonist or a virus-coded cytokine analogue such as EBV BCRF1 (Baer et al., 1984), whereas the Gram-positive bacterial strain preferably is a *Lactococcus species* and more preferably a *Lactococcus lactis*. Other Gram-positive bacterial strains to be used for the purpose of the current  
15 invention are *Bacillus subtilis*, *Streptococcus gordonii*, *Staphylococcus xylosus*, or a *Lactobacillus spec.* such as *Lactobacillus bulgaricus*, *Lactobacillus salivarius*, *Lactobacillus casei*, *Lactobacillus helveticus*, *Lactobacillus delbrueckii* or *Lactobacillus plantarum*.

The inflammatory bowel diseases such as a chronic colitis, Crohn's disease or  
20 an ulcerative colitis can be treated according to the invention with an appropriate dosage of the active cytokine compound, preferably IL-10 or soluble TNF receptor, and provides unexpectedly a restoration of the diseased colon to an apparently normal and healthy state.

25 IL-10 can be administered alone or in combination with at least one additional therapeutic agent. Examples of such agents include corticosteroids, sulphasalazine, derivatives of sulphasalazine, immunosuppressive drugs such as cyclosporin A, mercaptopurine, azathioprine, and another cytokine. The co-administration can be sequential or simultaneous. Co-administration generally  
30 means that the multiple (two or more) therapeutics are present in the recipient during a specified time interval. Typically, if a second agent is administered within the half-life of the first agent, the two agents are considered co-



administered.

The invention disclosed herein thus concerns a localised delivery of IL-10 through in situ synthesis by recombinant *L. Lactis*. As a result thereof the inflammation is reduced by 50% in chronic colitis induced with DSS and prevents the onset of colitis in IL-10  $-/-$  129 Sv/Ev mice. So the method is equally efficient in comparison to powerful, well-established and accepted therapies relying on the systemic administration of anti-inflammatory proteins.

The vector used here, *L. lactis*, is a Gram positive food grade organism which is totally harmless. It is a non-colonising micro-organism. Accurate dosage and timing during treatment, shown here to be of great importance, can thus easily be obtained.

The critical requirement for viability of the vector is shown in the current invention. This indicates the need for in situ synthesis of IL-10. The vector is indeed capable to achieve this by showing de novo synthesis of IL-10 in the colon.

An efficient novel concept for protein based treatment in the intestinal tract is herewith disclosed. The treatment can be given by the oral route, which is farmost desirable for pharmacological formulations. It can exert effects up to the distal colon using a compound with intrinsic sensitivity for the route used. This method bypasses the need for systemic administration. It opens the possibility for the localised delivery of substances, which are unstable or difficult to produce in high quantities. It is intrinsically very cost effective.

This method may answer the question for sustained and localised presence of IL-10 in therapy at concentrations higher than desirable or even achievable through systemic delivery, with regard to latent side effects.

Some terms used in the current description are, for sake of clarity, explained hereafter.

Generally, the term "symptoms" refers to any subjective evidence of disease or of a patient's condition. This includes evidence as perceived by the patient. Examples of symptoms of IBD include diarrhea, abdominal pain, fever, melena, hematochezia, and weight loss.

5

The term "signs" refers generally to any objective evidence of a disease or condition, usually as perceived by an examining physician or features which would reveal themselves on a laboratory evaluation or other tests such as an ultrasonic study or a radiographic test. Some examples of signs of IBD include abdominal mass, glossitis, aphtous ulcer, anal fissure, perianal fistula, anemia, malabsorption, and iron deficiency. Occasionally, signs and symptoms overlap. For example, the patient complains of blood stools (a symptom), and a laboratory test of a stool sample is positive for blood (a sign).

10

The phrase "appropriate dosage" or "effective amount" means an amount or dosage sufficient to ameliorate a symptom or sign of an autoimmune condition or of an undesirable or inappropriate inflammatory or immune response. An effective amount for a particular patient may vary depending on factors such as the condition being treated, the overall health of the patient, the method route and dose of administration and the severity of the side affects.

20

With "cytokine" is meant a polypeptide factor produced transiently by a range of cell types, acting usually locally, and activating the expression of specific genes by binding to cell surface receptors.

25

With "antagonist" is meant a compound that binds to but does not activate receptors, hence does inhibit the action of an agonist competitively.

"Agonists" are compounds that bind to and activate receptors (e.g., endogenous ligands such as hormones and neurotransmitters, chemically synthesized compounds, natural products like alkaloids).

30

Detailed description of the methods used in the current invention.

**Culture media**

GM17 is M17 (Difco, St. Louis) supplemented with 0.5 w/v % of glucose.

- 5 GM17E is GM17 supplemented with 5µg/ml of erythromycin. BM9 contains per liter 6 g of Na<sub>2</sub>HPO<sub>4</sub>, 3 g of KH<sub>2</sub>PO<sub>4</sub>, 1 g of NH<sub>4</sub>Cl, 0.5 g of NaCl, 2 mmol of MgSO<sub>4</sub>, 25 mmol of NaHCO<sub>3</sub>, 25 mmol of Na<sub>2</sub>CO<sub>3</sub>, 0.1 mmol of CaCl<sub>2</sub>, 5 g of glucose and 5 g of casitone (Difco). BM9E is BM9 supplemented with 5µg/ml of erythromycin.

10

**Recombinant DNA techniques.**

- PCR amplification of DNA was performed with VENT polymerase and using conditions recommended by the manufacturer. DNA modifying enzymes and restriction endonucleases were used under standard conditions and in the
- 15 buffers recommended by the manufacturers. General molecular cloning techniques and the electrophoresis of DNA and proteins were carried out essentially as described (Sambrook et al., 1990). *L. lactis* was transformed by electroporation of cells grown in the presence of glycine (Wells et al., 1993).

20 **Construction of the expression plasmids.**

- The plasmid pT1MIL10 (figure 1) was constructed by subcloning a PCR fragment, obtained with the primers (CAGTACAGCCGGAAGACAAT and GCACTAGTTAGCTTTTCATTTTGAT) and performed on a cDNA clone containing mlL10 coding sequence. For the design of this strategy we made
- 25 use of the mlL10 cDNA sequence as given in EMBL acc. nr. M37897. By utilization of the above mentioned primers, the mlL10 fragment could be subcloned as a blunt – SpeI fragment, after treatment with kinase and SpeI, in the NaeI-SpeI opened plasmid pT1NX (figure 1), which is a pTREX1 derivative (Wells and Schofield in : Lactic Acid Bacteria: current advances in metabolism, genetics and applications. F. Bozoglu & R. Bibek, Eds., Nato ASI Series H, Vol.98, p. 37. Springer-Verlag, 1996.)
- 30

The plasmid pT1TR5AH (figure 1) was constructed by subcloning a PCR

fragment, obtained with the primers (CTGGTCCCTTCTCTTGGTGAC and CCACTAGTCTATTAATGATGATGATGATGATGCGCAGTACCTGAGTCCTGG GG) and performed on a cDNA clone containing sTNFr55 coding sequence. For the design of this strategy we made use of the TNFr55 cDNA sequence as given in EMBL acc. nr. L26349. By utilizing the above mentioned primers, the sTNFr 55 fragment was provided with a 6his tag at the 3'end and could be subcloned as a blunt – SpeI fragment, after treatment with kinase and SpeI, in the NaeI-SpeI opened plasmid pT1NX.

Both plasmids code, downstream from the lactococcal P1 promotor, for fusion genes between the secretion leader from Usp45 (Van Asseldonk et al., Gene, 95, 155-160, 1990) and mIL10 and sTNFr 55, respectively. Upon secretion, the leader sequence is cleaved off.

#### Identification of recombinant proteins

Recombinant mIL10 and msTNFr 55 could be observed in the supernatant of cultures of MG1363[pT1MIL10] and MG1363[pT1TR5AH], respectively (figure 2). For this test, 5 ml aliquots of the cultures were extracted with 2 ml phenol and the proteins were subsequently prepared from the organic phase by precipitation with 10 ml of ethanol. A part of the precipitate, equivalent to 1 ml of culture supernatant, was subjected to SDS-15% PAGE and immunoblotting. Culture samples were taken at relevant times in the growth phase of the bacteria, as described below.

The culture supernatant of MG1363[pT1MIL10] contained, on average, 1  $\mu\text{g} \cdot \text{ml}^{-1}$  of murine IL10. Murine IL-10 activity of the supernatant was measured using a murine mast cell line MC/9 (Thompson-Snipes, L. et al., J. Exp. Med. 173, 507, 1991). Human IL-10 binds to murine IL-10R as was demonstrated by transfection experiments (Ho, A.S.Y et al., PNAS 90, 11267, 1993; Liu, Y. et al., J.Immunol. 152, 1821, 1994). 1  $\text{U} \cdot \text{ml}^{-1}$  of IL-10 is defined as the amount of IL-10 that is able to inhibit 50% the level of IFN-gamma production of conA activated splenocytes (Fiorentino, D.F. et al., J.Exp.Med. 170, 2081, 1989). The ED50 for this effect is typically 0.3-0.6  $\text{ng} \cdot \text{ml}^{-1}$ . When measured along with a standard of known activity (Biosource International, CA) the MG1363[pT1MIL10] culture

supernatant revealed an activity of approximately 8000 U.ml<sup>-1</sup>. Berg et al. (J. Clin. Invest 98, 1010-1020) report a specific activity of approximately 1.0 x 10<sup>7</sup> U.mg<sup>-1</sup> for recombinant mL10. From these considerations and taking into account the variations in the method used, we concluded that the recombinant mL10, present in the MG1363[pT1MIL10] culture supernatant, displayed full biological activity. No IL10 activity could be detected in the supernatant of the control cultures, MG1363 or MG1363[pTREX1].

The culture supernatant of strain MG1363[pT1TR5AH] contained, on average, 200 ng.ml<sup>-1</sup> msTNFr 55. Loetscher et al. (1991) showed that complete inhibition of TNF cytotoxic activity by sTNFr 55 was only obtained from a molar ratio of 1000 : 1 of sTNFr 55 to TNF and higher. The soluble recombinant TNFr 55 which had been recovered from the culture supernatant of MG1363(pT1TR5AH) showed an equal inhibitory effect on TNF as had been reported for the indigenous product. This was demonstrated by mixing up and thus competing out a titration series of TNF with a titration series of recombinant sTNFr and measuring TNF activity in a cytotoxicity assay as described (Espevik, T and Nissen-Meyer, 1986).

#### **Pretreatment of the mice**

For the induction of chronic colitis, mice were pre-treated as described by Kojouharoff et al. Clin Exp Immunol 107, 353, 1997. Six to eight weeks old female Balb/c mice received four cycles of treatment with DSS. Each cycle consisted of 5% DSS in the drinking water for 7 days, followed by a 10-day interval during which they received normal drinking water. Four to six weeks after completion of the last DSS cycle, mice were treated with the *L. lactis* strains as indicated.

### Legends to the figures.

Figure 1 : Overview of the plasmids used

Figure 1 a : schematic maps of the plasmids used. P1 is the lactococcal P1  
5 promoter as in Waterfield et al, (1995), usp45S is a DNA fragment encoding the  
secretion signal peptide from the lactococcal Usp45 (van Asseldonck et al,  
1990), mil 10 is a DNA fragment encoding the mature part of murine interleukin  
10, tr55 is a DNA fragment encoding the soluble part of type 1 TNF receptor,  
H6 is a fragment encoding 6 histidine residues, Em<sup>r</sup> is the erythromycin  
10 selection marker.

Figure 1b : DNA sequences of pTREX1 and pT1NX

Figure 1c : DNA sequences of pTIMIL10 and pT1TR5AH

Figure 2 :

15 Protein profile following SDS-PAGE of the culture supernatant of the indicated  
strains after immunoblot, revealed with anti-murine interleukin 10 (panel A) or  
anti-murine type 1 TNF receptor and anti-6 His (panel B) antisera.

Figure 3 :

20 Average of colon length of groups of mice in which: a) chronic colitis had been  
induced with DSS, b) chronic colitis had been induced with DSS and to which  
subsequently *L. lactis* strain MG1363pTREX1 was orally administered, c)  
chronic colitis had been induced with DSS and to which subsequently *L. lactis*  
strain MG1363pT1TR5AH was orally administered and d) chronic colitis had  
25 been induced with DSS and to which subsequently *L. lactis* strain  
MG1363pT1MIL10 was orally administered.

Figure 4 :

Average of epithelial damage score in the distal colon of groups of mice in  
30 which : a) chronic colitis had been induced with DSS, b) chronic colitis had  
been induced with DSS and to which subsequently *L. lactis* strain  
MG1363pTREX1 was orally administered, c) chronic colitis had been induced

with DSS and to which subsequently *L. lactis* strain MG1363pT1TR5AH was orally administered and d) chronic colitis had been induced with DSS and to which subsequently *L. lactis* strain MG1363pT1MIL10 was orally administered.

5 Figure 5 :

Average of inflammatory infiltrate score in the distal colon of groups of mice in which : a) chronic colitis had been induced with DSS, b) chronic colitis had been induced with DSS and to which subsequently *L. lactis* strain MG1363pTREX1 was orally administered, c) chronic colitis had been induced  
10 with DSS and to which subsequently *L. lactis* strain MG1363pT1TR5AH was orally administered and d) chronic colitis had been induced with DSS and to which subsequently *L. lactis* strain MG1363pT1MIL10 was orally administered.

Figure 6:

15 Representative sections of mice distal colon stained with haematoxylin and eosin.

normal tissue : untreated animals

DSS colitis : animals pretreated with DSS to acquire chronic colitis

DSS colitis, MG1363pT1MIL10 treatment : animals pretreated with DSS to  
20 acquire chronic colitis to which subsequently *L. lactis* strain MG1363pT1MIL10 was orally administered. DSS colitis, MG1363pTREX1 treatment : animals pretreated with DSS to acquire chronic colitis to which subsequently *L. lactis* strain MG1363pTREX1 was orally administered.

25 Figure 7:

Statistical evaluation of the histology. The colon sections were randomly numbered and interpreted blind. Scores from individual mice were subsequently decoded and the regrouped numbers were analysed statistically. The DSS colitis panel shows histological sumscores for the distal colon of blank mice and  
30 of mice induced with DSS to acquire chronic colitis, either untreated or treated with *L. lactis* cultures. The score is a sum of scores for epithelial damage and lymphoid infiltrate, both ranging between 0 and 4. Groups of mice (n = 10) were

alternatively treated with MG1363, MG1363(pTREX1) or MG1363(pT1MIL10) (= IL-10) for two (= 2w) or four (= 4w) weeks. Some of the cultures were irradiated with uv (= + uv) prior to inoculation, which reduced cell viability over  $10^6$  times. The IL-10-/- colitis panel shows histological sumscores of groups (n = 5) of 7 week old untreated, TREX treated and IL-10 treated female 129 Sv/Ev IL-10-/- mice. The histological score is a sum of the degree of inflammation in the proximal, middle and distal colon, all ranging between 0 and 4. Error bars represent s.e.m.

**Figure 8:**

Representation of bacterial viability after irradiation as measured at OD<sub>600</sub>.

In order to further disclose and thus clarify the current invention some examples are given hereunder.

### **Examples**

#### **Example 1.**

##### **Treatment of the mice with live *L. lactis***

Storage of expression strains.

Freshly streaked cultures of the *L. lactis* expression strains were inoculated in 10 ml of GM17 or GM17E depending on the absence or presence of an expression plasmid and grown overnight at 30°C. The overnight cultures were diluted 1/100 in fresh GM17 or GM17E and pregrown for 3 hours at 30°C. The cells were harvested by centrifugation and resuspended in BGM9 or BGM9E, depending on the presence of plasmids. These cultures were grown for 5 hours at 30°C. The protein profile of these cultures was analysed by performing Western immunoblotting on an equivalent of 1 ml of culture supernatant using either antiserum directed towards sTNFr 55 or IL10 respectively. The protein profile showed the presence of sTNFr 55 and IL10 in the appropriate lanes



(figure 2). 5 ml of the original GM17 or GM17E overnight cultures was supplemented with 5 ml of glycerol and stored at  $-20^{\circ}\text{C}$ . These stocks were used as starter material for several experiments. Protein analysis throughout a series of individual experiments showed that a high degree of reproducibility in the production of the recombinant proteins could be obtained by this procedure.

#### Weeks 1 and 2

Stock solutions of *L. lactis* strains were diluted 1/200 in 10 ml GM17 or GM17E and grown overnight at  $30^{\circ}\text{C}$ . The cells were harvested by centrifugation and resuspended in 1 ml BM9 or BM9E. Control, healthy mice and mice with induced colitis were inoculated on a daily basis with 100  $\mu\text{l}$  aliquots of these cell suspensions.

#### Weeks 3 and 4

Stock solutions of *L. lactis* strains were diluted 1/200 in 10 ml GM17 or GM17E and grown overnight at  $30^{\circ}\text{C}$ . These cultures were diluted 1/25 in 10 ml of BM9 or BM9E and grown for 3 hours at  $30^{\circ}\text{C}$ . Aliquots of 200  $\mu\text{l}$  were intragastrically (peroral) administered into mice on a daily basis.

### **Example 2.**

#### **Determination of histological score**

Histological score was determined essentially as described by Kojouharoff et al. Clin Exp Immunol 107, 353, 1997.

Mice were killed by cervical dislocation. The colon was removed and washed with PBS. The distal third of the colon was cut longitudinally, laid on filter paper and fixed with 10% formalin in PBS overnight. Sections of the paraffin-embedded material were made longitudinally. Three 3- $\mu\text{m}$  sections were cut at an intermediate distance of 200  $\mu\text{m}$ . The sections were stained with haematoxylin-eosin. Histological analysis was performed in blind fashion. Mice were scored individually, and each score represented the mean of three sections.

Histology was scored as follows:

Infiltration : 0, no infiltrate; 1, infiltrate around crypt bases; 2, Infiltrate reaching to L. muscularis mucosae; 3, extensive infiltration reaching the L. muscularis mucosae and thickening of the mucosa with abundant oedema; 4 infiltration of the L. submucosa.

Epithelial damage: 0, normal morphology; 1, loss of goblet cells; 2, loss of goblet cells in large areas; 3, loss of crypts; 4, loss of crypts in large areas and/or foci of polyploid regeneration.

Colonic length was measured immediately after dissection and placement on a paper towel.

The pathology of chronic colitis is, amongst other parameters, characterised by a decrease in length of the colon and by epithelial damage and infiltration of lymphocytes to a more or less substantial extent.

Figure 3 clearly shows an increase in colon length after the treatment of the inflamed mice with MG1363[pT1MIL10] and, although to a lesser extent, after the treatment of the mice with MG1363[pT1TR5AH].

Figure 4 and 5 show the onset of recovery from chronic colitis, in which mice treated with MG1363(pT1MIL10) appear to improve more extensively than those mice which had been treated with MG1363[pT1TR5AH].

Figure 4 shows the histological score of epithelial damage whereas figure 5 shows inflammatory infiltrate, both determined as described previously.

Figure 6 shows the histology of normal tissue, compared to inflamed and treated tissue.

In the normal histology one can observe a continuous array of crypts of equal length. In the crypts, numerous goblet cells can be observed. A low number of lymphocytes is present in the mucosa. No lymphocytes are present in the submucosa. In the inflamed tissue, one can see the disappearance of the organised crypt structures, ranging from differences in length to complete absence of structure. Also, in the relicts of the crypts no goblet cells are present. One can observe a large increase of the thickness of the mucosa due to a massive infiltration of lymphocytes. The lymphocytes tend to form

ulcerations. In severe cases, infiltration of lymphocytes can also be observed in the submucosa. The epithelium, however, remains intact. The negative control of treatment with MG1363( pTREX1) shows a pathology reminiscent of that of heavily inflamed tissue. Mice treated with MG1363 (pT1MIL10) show an almost complete restitution of the normal histology, revealing only slight remainders of infiltrating lymphocytes in the mucosa. Mice treated with MG1363[pT1TR5AH] show an intermediate degree in pathology.

Figure 7 shows the statistic evaluation of histological scores obtained from individual mice following treatment with the indicated *L. lactis* strains (group size = 10). The score was recorded after blind interpretation of slides from the distal colon as described (Kojouharoff et al.,1997). Each mouse was interpreted according to 3 longitudinal slides, equally spaced over the circumference of the colon. Both lymphoid infiltrate and epithelial damage were rated from 0 to 4 points and values for both parameters were summed for every mouse. Normal blank mice showed a histological score of 1 point. The mice induced for colitis are slightly over 5 points. All of the control groups for *L. lactis* treatment fluctuate around this number, with possibly a slightly higher tendency in some groups. The mice treated for 14 days with mIL-10 producing *L. lactis*, followed by 14 days of recovery however show an average of approximately 3 points. This is a decrease of nearly 50% in the pathology when measured against the difference between untreated and blank control groups. The reduction is significant ( $p = 0.0151$ ).

### **Example 3**

Due to the culture conditions used, a minor amount (40 ng) of mIL-10 is present in the supernatant of the inoculation suspension. To investigate whether this IL-10 brings about the observed reduction in the histological score we included treatment with UV killed IL-10 producer strains. These cultures were UV irradiated immediately prior to the inoculation. Figure 8 shows that irradiation reduced the bacterial viability to less than 1 in  $10^6$  cfu so that no further accumulation of IL-10 was observed. This was not associated with cell lysis

since no drop in  $OD_{600}$  was observed and no IL-10 precursor could be detected in the culture supernatant. The irradiation does not affect IL-10 bioactivity. Diseased mice treated for 2 or 4 weeks with the UV dispatched cultures show no difference in colon histology when compared to any of the control groups positive for enterocolitis. The fate of the residual IL-10 in the inoculation medium is most likely denaturation and breakdown in the stomach and duodenum. The acidity of the stomach, prior at pH 1,5, rises to pH6 immediately after inoculation. After 5 minutes a pH of 4 is reached, which further drops from 3,5 to 2,5 in the interval between 30 and 60 minutes after inoculation. IL-10 detected in the stomach 5 minutes after inoculation rapidly decreases in concentration and was only found in trace amounts in the duodenum at 30 minutes after inoculation. At later time-points no IL-10 was detected here nor in the jejunum or ileum.

#### 15 **Example 4**

Seven serial inoculations of  $3,4 \cdot 10^9$  cfu of MG1363(pT1MIL10) were given to 129 Sv/Ev IL-10-/- mice, thereby respecting 1 hour intervals. The intestine was prepared out 30 minutes after the last inoculation and divided in the morphologic compartments. Immediately the tissues were homogenised in PBS with 1% BSA and 0,05%  $NaN_3$ . Cfus of MG1363(pT1MIL10) were determined as  $7 \cdot 10^6$  in the stomach,  $2,6 \cdot 10^8$  in the duodenum,  $2,8 \cdot 10^7$  in the jejunum,  $4 \cdot 10^8$  in the ileum,  $8,4 \cdot 10^8$  in the caecum and  $7 \cdot 10^8$  in the colon. We have detected 70 ng of soluble IL-10 in the colon homogenate. None of the upstream compartments showed any IL-10 content. From this it is concluded that recombinant *L. lactis* can actively produce IL-10 in the colon.

### Example 5

#### **Prevention of enterocolitis in IL10<sup>-/-</sup> mice**

5 The capacity of the approach described above was tested to prevent the onset of colitis in 129 Sv/Ev IL10<sup>-/-</sup> mice. These mice spontaneously develop a generalized enterocolitis in the frame between three and eight weeks of age (Kuhn et al., Cell, 1993; 75:263-274). Inflammatory changes first appear in the cecum, ascending and transverse colon of 3-wk-old mutants. Progressive  
10 disease in ageing IL10<sup>-/-</sup> mice was characterised by an increased number of multifocal inflammatory cell infiltrates composed of mononuclear cells and neutrophils accompanied by moderate epithelial hyperplasia and slight mucin depletion from goblet cells. Small epithelial erosions and crypt abscesses were occasionally present and inflammation rarely involved the submucosa. IL10<sup>-/-</sup>  
15 mice used in our studies showed a less severe inflammation as described due to "clean" rather than "conventional" conditions of our animal facility.

When these mice are treated from week 3 on for 6 to 8 weeks with either anti IFN- $\gamma$  or anti-IL-12 colitis can be prevented (Rennick et al., J-Leukoc-Biol., 1997 Apr; 61(4):389-396). We treated 3 weeks old mice by daily intra-gastric  
20 inoculation with IL-10 producing *L. lactis*. The mice were treated for 4 weeks with either mid-log or end-log cultures whilst an untreated group was kept under identical conditions. Figure 7 shows histological scores obtained as described (Berg et al., J-Clin-Invest; 1996, Aug 15; 98(4):1010-1020), with the exception that we did not examine the caecum. The non-treated mice show a mean  
25 histological score of approximately 4,5 points. This fits well with reported data, provided one takes into account the contribution of the caecal scores in these values and the slight age difference. The group of mice treated with MG1363(pT1MIL10) shows a mean histological score of 1,5 points which is only slightly over values reported for 3 week old mice (Berg et al., J-Clin-Invest; 1996, Aug 15; 98(4):1010-1020). As it is the sum of 3 values ranging from  
30 0 to 4 points, this is considered as a very low score. From these data it is clear that the development of colitis can be prevented by this treatment.

## References

- Wells J.M., & Schofield, K.M. Cloning and expression vectors for lactococci From: Lactic Acid Bacteria (eds Bozoglu B., and Ray, B.) NATO ASI Series H 98: 37-63  
5 Springer-Verlag, Berlin, Heidelberg (1996).
- Kojouharoff, G., Hans, W., Obermeier, F., Mannel, D.N., Andus, T., Scholmerich, J., Gross, V. & Falk, W. Neutralization of tumour necrosis factor (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice. Clin.  
10 Exp. Immunol. 107, 353 - 358, 1997.
- Van Asseldonk, M., Rutten, G., Oteman, M., Siezen, R.J., de Vos, W.M. and Simons, G. Cloning of usp45, a gene encoding a secreted protein from *Lactococcus lactis* subsp. *lactis* MG1363. Gene 95, 155-160 (1990).  
15
- Sambrook, J., Fritsch, E.F., and Maniatis T. Molecular cloning-a laboratory manual. Cold Spring Harbor Laboratory, New York (1990).
- Wells, J.M., Wilson, P.W., and Le Page, R.W.F. Improved cloning vectors and  
20 transformation procedure for *Lactococcus lactis*. J. Appl. Bacteriol. 74, 629-636 (1993).
- Schlaak, J.F., Schmitt, E., Huls, C., Meyer zum Buschenfelde, K.H. & Fleischer, B. A sensitive and specific bioassay for the detection of human interleukin-10. J. Immunol. Methods 168, 49-54, 1994.  
25
- Thompson-Snipes, L., Dhar, V., Bond, M.W., Mosmann, T.R., Moore, K.W. & Rennick, DM Interleukin 10: a novel stimulatory factor for mast cells and their progenitors. J. Exp. Med. 173, 507-10, 1991.
- 30 Ho, A., S., Y., Liu, Y., Khan, T., A., Hsu, D., H., Bazan, J., F. & Moore, K., W. A receptor for interleukin 10 is related to interferon receptors. Proceedings of the National Academy of Sciences of the United States of America 90(23): 11267-11271 (1993)

Liu, Y., Wei, S., H., Y., Ho, A., S., Y., De Waal-Malefyt, R. & Moore, K., W. Expression cloning and characterization of a human IL-10 receptor. *Journal of Immunology* 152(4): 1821-1829 (1994)

- 5    Fiorentino, D.F., Bond, M.W. & Mosmann, T.R. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. *J-Exp-Med.* 170, 2081-95, 1989.

- Waterfield, N.R. et al., The isolation of lactococcal promoters and their use in  
10    investigating bacterial luciferase synthesis in *Lactococcus lactis*. *Gene*, 165, 9-15 (1995).

Baer, R. et al., DNA sequence and expression of the B95-8 Epstein-Barr virus genome. *Nature*, 130, 207-211 (1984).

## Claims

1. Use of a cytokine-producing Gram-positive bacterial strain or a cytokine antagonist-producing Gram-positive bacterial strain for the preparation of a medicament to treat inflammatory bowel disease.
2. Use of a Gram-positive bacterial strain according to claim 1 wherein the cytokine or cytokine antagonist is IL-10, a soluble TNF receptor or another TNF antagonist, an IL-12 antagonist, an Interferon- $\gamma$  antagonist, an IL-1 antagonist or a virus-coded cytokine analogue such as EBV BCRF1.
3. Use of a Gram-positive bacterial strain according to claim 1 or 2 wherein the Gram-positive bacterial strain is a *Lactococcus species*.
4. Use of a Gram-positive bacterial strain according to claim 3 wherein the *Lactococcus species* is *Lactococcus lactis*.
5. Use of a Gram-positive bacterial strain according to claim 1 or 2 wherein the Gram-positive bacterial strain is *Bacillus subtilis*, *Streptococcus gordonii*, *Staphylococcus xylosus*, or a *Lactobacillus spec*.
6. Use of a Gram-positive bacterial strain according to any of the preceeding claims wherein the bowel disease is a chronic colitis, Crohn's disease or an ulcerative colitis.



1/10




Figure 1a

2/10-1

## pTREX1 Figure 1B

GAATTCGATTAAAGTCATCTTACCTCTTTTATTAGTTTTTCTTATAATCTAATGATAACATTT  
TTATAATTAATCTATAAACCATATCCCTCTTTGGAATCAAAATTTATTATCTACTCCTTTGTA  
GATATGTTATAATAACAAGTATCAGATCTGGGAGACCACAACGGTTTCCCCTAGAAATAA  
TTTTGTTTAACTTTAGAAAGGAGATATACGCATGCAGGATATCTCTAGAATGGATCCGGC  
TGCTAACAAAGCCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAG  
CATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTGCTGAAAGGAGGAACT  
ATATCCGGATGACCTGCAGGCAAGCTCTAGAATCGATACGATTTTGAAGTGGCAACAGA  
TAAAAAAAAGCAGTTTAAATTTGTTGCTGAACCTTTTAAACAAGCAAATACAATCATTGTC  
GCAACAGATAGCGACAGAGAAGGCGAAAACATTGCCTGGTCGATCATTATAAAGCAAA  
TGCCTTTTCTAAAGATAAAACGTATAAAAGACTATGGATCAATAGTTTAGAAAAAGATGTG  
ATCCGTAGCGGTTTTCAAATTTGCAACCAGGAATGAATTACTATCCCTTTTATCAAGAAG  
CGCAAAAGAAAAACGAAATGATACACCAATCAGTGCAAAAAAAGATATAATGGGAGATAA  
GACGGTTCGTGTTTCGTGCTGACTTGACCATATCATAAAAAATCGAAACAGCAAAGAATGG  
CGGAAACGTAAAGAAGTTATGGAAATAAGACTTAGAAGCAAACCTTAAGAGTGTGTTGAT  
AGTGCAGTATCTTAAATTTTTGTATAATAGGAATTGAAGTTAAATTAGATGCTAAAAATTTG  
TAATTAAGAAGGAGTGATTACATGAACAAAAATATAAAATATTCTCAAACTTTTTAACGA  
GTGAAAAAGTACTCAACCAATAATAAAACAATTGAATTTAAAGAAACCGATACCGTTTA  
CGAAATTGGAACAGGTAAAGGGCATTTAACGACGAACTGGCTAAAATAAGTAAACAGG  
TAACGTCTATTGAATTAGACAGTCATCTATTCAACTTATCGTCAGAAAAATTAAACTGAA  
TACTCGTGTCACCTTAATTCACCAAGATATTCTACAGTTTCAATTCCCTAACAAACAGAGG  
TATAAAATTGTTGGGAGTATTCCTTACCATTAAAGCACACAAATTATTAAAAAAGTGGTTTT  
TGAAAGCCATGCGTCTGACATCTATCTGATTGTTGAAGAAGGATTCTACAAGCGTACCTT  
GGATATTCACCGAACACTAGGGTTGCTCTTGACACTCAAGTCTCGATTACAGCAATTGCT  
TAAGCTGCCAGCGGAATGCTTTCATCCTAAACCAAAAAGTAAACAGTGTCTTAATAAACT  
TACCCGCCATACCACAGATGTTCCAGATAAATATTGGAAGCTATATACGTACTTTGTTTCA  
AATGGGTCAATCGAGAATATCGTCAACTGTTTACTAAAAATCAGTTTCATCAAGCAATGA  
AACACGCCAAAGTAAACAATTTAAGTACCGTTACTTATGAGCAAGTATTGTCTATTTTTAA  
TAGTTATCTATTATTTAACGGGAGGAAATAATTCTATGAGTCGCTTTTGTAAATTTGGAAA  
GTTACACGTTACTAAAGGGAATGTAGATAAATTATTAGGTATACTACTGACAGCTTCCAA  
GGAGCTAAAGAGGTCCCTAGCGCTCTTATCATGGGGAAGCTCGGATCATATGCAAGACA  
AAATAAACTCGCAACAGCACTTGAGAGAAATGGGACGAATCGAGAAAACCTCTTTACGC  
TGGATTACATATCTAATAAAGCCGTAAGGAGACGGGTTCAAAAAGGTTTAAATAAAGGAG  
AAGCAATCAATGCATTAGCTAGAACTATATTTTTTGACAACGTGGAGAATTTAGAGAAC  
GTGCTCTCCAAGACCAGTTACAAAGAGCTAGTGCACTAAACATAATTATTAACGCTATAA  
GTGTGTGGAACACTGTATATATGGAAAAAGCCGTAGAAGAATTAAAGCAAGAGGAGAA  
TTTAGAGAAGATTTAATGCCATATGCGTGGCCGTTAGGATGGGAACATATCAATTTTCTT  
GGAGAATACAAATTTGAAGGATTACATGACACTGGGCAAATGAATTTACGTCTTTACGT  
ATAAAAGAGCCGTTTTATTCTTAATATAACGGCTCTTTTTATAGAAAAATCCTTAGCGTG  
GTTTTTTTCCGAAATGCTGGCGGTACCCCAAGAATTAGAAATGAGTAGATCAAATTATTC  
ACGAATAGAATCAGGAAAATCAGATCCAACCATAAAAACACTAGAACAAATTGCAAAGTT  
AACTAACTCAACGCTAGTAGTGGATTTAATCCCAAATGAGCCAACAGAACAGAGCCAG  
AAACAGAATCAGAACAAGTAACATTGGATTTAGAAATGGAAGAAGAAAAAAGCAATGACT  
TCGTGTGAATAATGCACGAAATCGTTGCTTATTTTTTTTTTAAAGCGGTATACTAGATATA  
ACGAAACAACGAACTGAATAGAAACGAAAAAAGAGCCATGACACATTTATAAAATGTTTG  
ACGACATTTTATAAATGCATAGCCCGATAAGATTGCCAAACCAACGCTTATCAGTTAGTC  
AGATGAACTCTTCCCTCGTAAGAAGTTATTTAATTAACCTTTGTTTGAAGACGGTATATAAC  
CGTACTATCATTATATAGGGAAATCAGAGAGTTTTCAAGTATCTAAGCTACTGAATTTAAG  
AATTGTAAAGCAATCAATCGGAAATCGTTTGATTGCTTTTTTTGTATTCAATTTATAGAAGGT  
GGAGTTTGTATGAATCATGATGAATGTAAACTTATATAAAAAATAGTTTATTGGAGATAA

***SUBSTITUTE SHEET (RULE 26)***

2/10-2

pTREX1 (cont.)      Figure 1B (cont.)

GAAAATTAGCAAATATCTATACACTAGAAACGTTTAAAGAAAGAGTTAGAAAAGAGAAATAT  
CTACTTAGAAACAAAATCAGATAAGTATTTTTCTTCGGAGGGGGAAGATTATATATATAAG  
TTAATAGAAAATAACAAAATAATTTATTTCGATTAGTGGAAGGAAATTTGACTTATAAAGGAAA  
AAAATCTTTTTCAAAACATGCAATATTGAAACAGTTGAATGAAAAAGCAAACCAAGTTAAT  
TAAACAACCTATTTTATAGGATTTATAGGAAAGGAGAACAGCTGAATGAATATCCCTTTTG  
TTGTAGAAACTGTGCTTCATGACGGCTTGTTAAAGTACAAATTTAAAAATAGTAAATTCG  
CTCAATCACTACCAAGCCAGGTAAAAGCAAAGGGGCTATTTTTGCGTATCGCTCAAAATC  
AAGCATGATTGGCGGTCGTGGTGTTGTTCTGACTTCCGAGGAAGCGATTCAAGAAAATC  
AAGATACATTTACACATTGGACACCCAACGTTTATCGTTATGGAACGTATGCAGACGAAA  
ACCGTTCATACACGAAAGGACATTCTGAAAACAATTTAAGACAAATCAATACCTTCTTTAT  
TGATTTTGATATTCACACGGCAAAAGAACTATTTTCAGCAAGCGATATTTTAACAACCGCT  
ATTGATTTAGGTTTTATGCCTACTATGATTATCAAATCTGATAAAGGTTATCAAGCATATTT  
TGTTTTAGAAACGCCAGTCTATGTGACTTCAAATCAGAATTTAAATCTGTCAAAGCAGCC  
AAAATAATTTTCGCAAAATATCCGAGAATATTTTGAAAGTCTTTGCCAGTTGATCTAACGT  
GTAATCATTTTGGTATTGCTCGCATACCAAGAACGGACAATGTAGAATTTTTTGATCCTAA  
TTACCGTTATTCTTTCAAAGAATGGCAAGATTGGTCTTTCAAACAAACAGATAATAAGGGC  
TTTACTCGTTCAAGTCTAACGGTTTTAAGCGGTACAGAAGGCAAAAAACAAGTAGATGAA  
CCCTGGTTTAATCTCTTATTGCACGAAACGAAATTTTCAGGAGAAAAGGGTTTAATAGGG  
CGTAATAACGTCATGTTTACCCTCTCTTTAGCCTACTTTAGTTCAGGCTATTCAATCGAAA  
CGTGCGAATATAATATGTTTGAGTTTAATAATCGATTAGATCAACCCTTAGAAGAAAAAGA  
AGTAATCAAAATTGTTAGAAGTGCCTATTCAGAAAATCAAGGGGCTAATAGGGAATA  
CATTACCATTCTTTGCAAAGCTTGGGTATCAAGTGATTAAACCAGTAAAGATTTATTTGTC  
CGTCAAGGGTGGTTTAAATTCAAGAAAAAAGAAGCGAACGTCAACGTGTTTCAATTTGTCA  
GAATGGAAAGAAGATTTAATGGCTTATATTAGCGAAAAAAGCGATGTATACAAGCCTTAT  
TTAGTGACGACCAAAAAAGAGATTAGAGAAGTGCTAGGCATTCCTGAACGGACATTAGA  
TAAATTGCTGAAGGTACTGAAGGCGAATCAGGAAATTTCTTTAAGATTAACCAGGAAG  
AAATGGTGGCATTCAACTTGCTAGTGTTAAATCATTGTTGCTATCGATCATTAAAGTAAAA  
AAAGAAGAAAAAGAAAGCTATATAAAGGCGCTGACAAATCTTTTGAAGTATAGAGCATACA  
TTCATTCAAGAGACTTTAAACAAGCTAGCAGAACGCCCTAAACGGACACACAACCTCGAT  
TTGTTTAGCTATGATACAGGCTGAAAATAAAACCCGCACTATGCCATTACATTTATATCTA  
TGATACGTGTTTGTCTTTCTTTGCTGTTTAGCGAATGATTAGCAGAAATATACAGAGTAA  
GATTTTAATTAATTATTAGGGGGGAGAAGGAGAGAGTAGCCCGAAAACCTTTTAGTTGGCTT  
GGACTGAACGAAGTGAGGGAAAGGCTACTAAAACGTGCGAGGGGGCAGTGAGAGCGAAG  
CGAACACTTGATTTTTTAATTTTCTATCTTTATAGGTCATTAGAGTATACTTATTTGTCCT  
ATAAACTATTTAGCAGCATAATAGATTTATTGAATAGGTCATTTAAGTTGAGCATATTAGA  
GGAGGAAAATCTTGGAGAAATATTTGAAGAACCCGATTACATGGATTGGATTAGTTCTTG  
TGGTTACGTGGTTTTTAAGTAAAGTAGTGAATTTTTGATTTTTGGTGTGTGTCTTGTT  
GTTAGTATTTGCTAGTCAAAGTGATTAATA

2/10-3

pT1NX Figure 1B (cont.)

GAATTCGATTAAGTCATCTTACCTCTTTTATTAGTTTTTTCTTATAATCTAATGATAACATTT  
TTATAATTAATCTATAAACCATATCCCTCTTTGGAATCAAAATTTATTATCTACTCCTTTGTA  
GATATGTTATAATACAAGTATCAGATCTGGGAGACCACAACGGTTTCCCACTAGAAATAA  
TTTTGTTTAACTTTAGAAAGGAGATATACGCATGAAAAAAAAGATTATCTCAGCTATTTTAA  
TGTCTACAGTCATACTTTCTGCTGCAGCCCCGTTGTCAGGTGTTTACGCCGGCGACGGA  
TCCAAAAGAGGAAGACAATAACAAGCCTGGCAAAGAAGACAATAACAAGCCTGGCAAAG  
AAGACAATAACAAGCCTGGCAAAGAAGACAACAACAAGCCTGGCAAAGAAGACAACAAC  
AAGCCTGGTAAAGAAGACAACAACAAGCCTGGCAAAGAAGACGGCAACAAGCCTGGTAA  
AGAAGACAACAACAAAAACCTGGTAAAGAAGATGGCAACAAGCCTGGTAAAGAAGACAACA  
AAAAACCTGGTAAAGAAGACGGCAACAAGCCTGGCAAAGAAGATGGCAACAACCTGGT  
AAAGAAGATGGTAACGGAGTACATGTCGTTAAACCTGGTGATACAGTAAATGACATTGCA  
AAAGCAAACGGCACTACTGCTGACAAAATTGCTGCAGATAACAAATTAGCTGATAAAAAC  
ATGATCAAACCTGGTCAAGAACTTGTGTTGATAAGAAGCAACCAGCAAACCATGCAGAT  
GCTAACAAAGCTCAAGCATTACCAGAACTGGCGAAGAAAATCCATTCATCGGTACAAC  
GTATTTGGTGGATTATCATTAGCCTTAGGTGCAGCGTTATTAGCTGGACGTCGTCGCGA  
ACTATAACTAGTAGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTG  
CCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCTCTAACGGGTCTTGAGGGGT  
TTTTTGCTGAAAGGAGGAACATATCCGGATGACCTGCAGGCAAGCTCTAGAATCGATA  
CGATTTTGAAGTGGCAACAGATAAAAAAAGCAGTTTAAATTTGTTGCTGAACCTTTTAAAA  
CAAGCAAATACAATCATTGTCGCAACAGATAGCGACAGAGAAGGGCGAAAACATTGCCTG  
GTCGATCATTATAAAGCAAATGCCTTTTCTAAAGATAAAACGTATAAAAGACTATGGATC  
AATAGTTTGAAGAAAGATGTGATCCGTAGCGGTTTTCAAATTTGCAACCAGGAATGAAT  
TACTATCCCTTTTATCAAGAAGCGCAAAAGAAAAACGAAATGATACACCAATCAGTGCAA  
AAAAAGATATAATGGGAGATAAGACGGTTCGTGTTCTGTGCTGACTTGCACCATATCATAA  
AAATCGAAACAGCAAAGAATGGCGGAAACGTAAAAGAAGTTATGGAAATAAGACTTAGAA  
GCAAACCTAAGAGTGTGTTGATAGTGCAAGTATCTTAAATTTTGATAATAGGAATTGAAG  
TTAAATTAGATGCTAAAAATTTGTAATTAAGAAGGAGTGATTACATGAACAAAAATATAAA  
ATATTCTCAAACTTTTTAACGAGTGAAAAAGTACTCAACCAAATAATAAAACAATTGAATT  
TAAAAGAAACCGATACCGTTTACGAAATTGGAACAGGTAAAGGGCATTTAACGACGAAAC  
TGGCTAAAATAAGTAAACAGGTAAACGTCTATTGAATTAGACAGTCATCTATTCAACTTATC  
GTCAGAAAAATTAACCTGAATACTCGTGTCACTTTAATTACCAAGATATTCTACAGTTT  
CAATTCCCTAACAAACAGAGGTATAAAATTGTTGGGAGTATTCTTACCATTTAAGCACAC  
AAATTATTAAGAAAGTGGTTTTTGAAGCCATGCGTCTGACATCTATCTGATTGTTGAAGA  
AGGATTCTACAAGCGTACCTTGATATTACCGAACACTAGGGTTGCTCTTGACACTCA  
AGTCTCGATTGAGCAATTGCTTAAGCTGCCAGCGGAATGCTTTCATCCTAAACCAAAGT  
AAACAGTGTCTTAATAAACTTACCCGCCATACCACAGATGTTCCAGATAAATATTGGAA  
GCTATATACGTACTTTGTTTCAAATGGGTCAATCGAGAATATCGTCAACTGTTTACTAAA  
AATCAGTTTCATCAAGCAATGAAACACGCCAAAGTAAACAATTTAAGTACCGTTACTTATG  
AGCAAGTATTGTCTATTTTTAATAGTTATCTATTATTTAACGGGAGGAAATAATTCTATGAG  
TCGCTTTTGTAATTTGGAAGTTACACGTTACTAAAGGGAATGTAGATAAATTATTAGGT  
ATACTACTGACAGCTTCCAAGGAGCTAAAGAGGTCCCTAGCGCTCTTATCATGGGGGAAG  
CTCGGATCATATGCAAGACAAAATAAACTCGCAACAGCACTTGGAGAAATGGGACGAAT  
CGAGAAAACCCCTCTTTACGCTGGATTACATATCTAATAAAGCCGTAAGGAGACGGGTTC  
AAAAGGTTTTAATAAAGGAGAAGCAATCAATGCATTAGCTAGAACTATATTTTTTGGACAA  
CGTGGAGAATTTAGAGAACGTGCTCTCCAAGACCAGTTACAAAGAGCTAGTGCACTAAA  
CATAATTATTAACGCTATAAGTGTGTGGAACACTGTATATATGGAAAAAGCCGTAGAAGA  
ATTAAAAGCAAGAGGAGAATTTAGAGAAGATTTAATGCCATATGCGTGGCCGTTAGGATG  
GGAACATATCAATTTTCTTGAGAATACAAATTTGAAGGATTACATGACACTGGGCAAAT  
GAATTTACGTCTTTACGTATAAAAGAGCCGTTTTATTCTTAATATAACGGCTCTTTTTATA  
GAAAAAATCCTTAGCGTGTTTTTTCCGAAATGCTGGCGGTACCCCAAGAATTAGAAAT

***SUBSTITUTE SHEET (RULE 26)***

2/10-4

pT1NX (cont.) Figure 1B (cont.)

GAGTAGATCAAATTATTCACGAATAGAATCAGGAAAATCAGATCCAACCATAAAAACTA  
GAACAAATTGCAAAGTTAACTAACTCAACGCTAGTAGTGGATTTAATCCCAAATGAGCCA  
ACAGAACCAGAGCCAGAAACAGAATCAGAACAAGTAACATTGGATTTAGAAATGGAAGA  
AGAAAAAAGCAATGACTTCGTGTGAATAATGCACGAAATCGTTGCTTATTTTTTTTAAAA  
GCGGTATACTAGATATAACGAAACAACGAACTGAATAGAAACGAAAAAAGAGCCATGACA  
CATTTATAAAATGTTTGACGACATTTTATAAATGCATAGCCCGATAAGATTGCCAAACCAA  
CGCTTATCAGTTAGTCAGATGAACTCTTCCCTCGTAAGAAGTTATTTAATTAACTTTGTTT  
GAAGACGGTATATAACCGTACTATCATTATATAGGGAAATCAGAGAGTTTTCAAGTATCTA  
AGCTACTGAATTTAAGAATTGTTAAGCAATCAATCGGAAATCGTTTGATTGCTTTTTTTGT  
ATTCATTTATAGAAGGTGGAGTTTGTATGAATCATGATGAATGTAAACTTATATAAAAAA  
TAGTTTATTGGAGATAAGAAAATTAGCAAATATCTATACACTAGAAACGTTTAAGAAAGAG  
TTAGAAAAGAGAAATATCTACTTAGAAACAAAATCAGATAAGTATTTTTCTTCGGAGGGG  
GAAGATTATATATAAGTTAATAGAAAATAACAAAATAATTTATTTCGATTAGTGGAaaaaa  
ATTGACTTATAAAGGAAAAAAATCTTTTTCAAACATGCAATATTGAAACAGTTGAATGAA  
AAAGCAAACCAAGTTAATTAAACAACCTATTTTATAGGATTTATAGGAAAGGAGAACAGCT  
GAATGAATATCCCTTTTGTGTAGAAACTGTGCTTCATGACGGCTTGTTAAAGTACAAATT  
TAAAAATAGTAAATTCGCTCAATCACTACCAAGCCAGGTAAAAGCAAAGGGGCTATTTT  
TGCGTATCGCTCAAAATCAAGCATGATTGGCGGTCGTGGTGTGTTCTGACTTCCGAGG  
AAGCGATTCAAGAAAATCAAGATACATTTACACATTGGACACCCAACGTTTATCGTTATG  
GAACGTATGCAGACGAAAACCGTTCATACACGAAAGGACATTCTGAAAACAATTTAAGAC  
AAATCAATACCTTCTTTATTGATTTTGATATTCACACGGCAAAGAAACTATTTTCAGCAAG  
CGATATTTTAACAACCGCTATTGATTTAGGTTTTATGCCTACTATGATTATCAAACTGATA  
AAGGTTATCAAGCATATTTTGTTTAGAAACGCCAGTCTATGTGACTTCAAAATCAGAATT  
TAAATCTGTCAAAGCAGCCAAAATAATTTGCAAAATATCCGAGAATATTTTGGAAAGTCT  
TTGCCAGTTGATCTAACGTGTAATCATTGTTGCTCGCATACCAAGAACGGACAAT  
GTAGAATTTTTTGATCCTAATTACCGTTATTCTTTCAAAGAATGGCAAGATTGGTCTTTCA  
AACAAACAGATAATAAGGGCTTACTCGTTCAAGTCTAACGGTTTTAAGCGGTACAGAAG  
GCAAAAAACAAGTAGATGAACCCTGGTTTAATCTCTTATTGCACGAAACGAAATTTTCAG  
GAGAAAAGGGTTTAATAGGGCGTAATAACGTCATGTTTACCCTCTCTTTAGCCTACTTTA  
GTTTCAGGCTATTCAATCGAAACGTGCGAATATAATATGTTTGAGTTTAATAATCGATTAGA  
TCAACCCTTAGAAGAAAAAAGAAGTAATCAAAATTGTTAGAAGTGCCTATTAGAAAACCTAT  
CAAGGGGGCTAATAGGGAATACATTACCATTCTTTGCAAAGCTTGGGTATCAAGTGATTTA  
ACCAGTAAAGATTTATTTGTCCGTCAAGGGTGGTTTAAATTCAAGAAAAAAGAAGCGAA  
CGTCAACGTGTTTCATTTGTCAGAATGGAAAGAAGATTTAATGGCTTATATTAGCGAAAAA  
AGCGATGTATACAAGCCTTATTTAGTGACGACCAAAAAAGAGATTAGAGAAGTGCTAGG  
CATTCCTGAACGGACATTAGATAAATTGCTGAAGGTACTGAAGGCGAATCAGGAAATTTT  
CTTTAAGATTAACCCAGGAAGAAATGGTGGCATTCAACTTGCTAGTGTTAAATCATTGTTG  
CTATCGATCATTAAGTAAAAAAGAAGAAAAAGAAAGCTATATAAAGGCGCTGACAAAT  
TCTTTTGACTTAGAGCATACATTCATTCAAGAGACTTTAAACAAGCTAGCAGAACGCCCT  
AAAACGGACACACAACCTCGATTTGTTTAGCTATGATACAGGCTGAAAATAAAACCCGCAC  
TATGCCATTACATTTATATCTATGATACGTGTTTGTGTTTTCTTTGCTGTTTAGCGAATGAT  
TAGCAGAAATATACAGAGTAAGATTTTAATTAATTATTAGGGGGAGAAGGAGAGAGTAGC  
CCGAAAACCTTTAGTTGGCTTGGACTGAACGAAGTGAGGGAAAGGCTACTAAAACGTGCG  
AGGGGCGAGTGAGAGCGAAGCGAACACTTGATTTTTTAATTTTCTATCTTTTATAGGTCATT  
AGAGTATACTTATTTGTCCTATAAACTATTTAGCAGCATAATAGATTTATTGAATAGGTCAT  
TTAAGTTGAGCATATTAGAGGAGGAAAATCTTGGAGAAATATTTGAAGAACCCGATTACA  
TGGATTGGATTAGTTCTTGTGGTTACGTGGTTTTTAATAAAGTAGTGAATTTTTGATTT  
TTGGTGTGTGTCTTGTGTTAGTATTTGCTAGTCAAAGTGATTAATA

***SUBSTITUTE SHEET (RULE 26)***

3/10-1

pT1MIL10 Figure 1c

GAATTCGATTAAGTCATCTTACCTCTTTTATTAGTTTTTCTTATAATCTAATGATAACATTT  
TTATAATTAATCTATAAACCATATCCCTCTTTGGAATCAAAATTTATTATCTACTCCTTTGTA  
GATATGTTATAATACAAGTATCAGATCTGGGAGACCACAACGGTTTCCCACTAGAAATAA  
TTTTGTTTAACTTTAGAAAGGAGATATACGCATGAAAAAAAAGATTATCTCAGCTATTTTAA  
TGTCTACAGTCATACTTTCTGCTGCAGCCCCGTTGTCAGGTGTTTACGCCAGTACAGC  
CGGGAAGACAATAACTGCACCCACTTCCCAGTCGGCCAGAGCCACATGCTCCTAGAGCT  
GCGGACTGCCTTCAGCCAGGTGAAGACTTTCTTTCAAACAAAGGACCAGCTGGACAACA  
TACTGCTAACCGACTCCTTAATGCAGGACTTTAAGGGTTACTTGGGTTGCCAAGCCTTAT  
CGGAAATGATCCAGTTTTACCTGGTAGAAGTGATGCCCCAGGCAGAGAAGCATGGCCCA  
GAAATCAAGGAGCATTGGAATCCCTGGGTGAGAAGCTGAAGACCCTCAGGATGCGGCT  
GAGGCGCTGTCATCGATTTCTCCCCTGTGAAAATAAGAGCAAGGCAGTGGAGCAGGTG  
AAGAGTGATTTTAATAAGCTCCAAGACCAAGGTGTCTACAAGGCCATGAATGAATTTGAC  
ATCTTCATCAACTGCATAGAAGCATACATGATGATCAAAATGAAAAGCTAACTAGTAGATC  
CGGCTGCTAACAAAGCCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATA  
ACTAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTGCTGAAAGGAG  
GAACTATATCCGGATGACCTGCAGGCAAGCTCTAGAATCGATACGATTTTGAAGTGCCA  
ACAGATAAAAAAAGCAGTTTAAATTTGTTGCTGAACTTTTAAAACAAGCAAATACAATCA  
TTGTCGCAACAGATAGCGACAGAGAAGGCGAAAACATTGCCTGGTTCGATCATTCAATAA  
GCAAATGCCTTTTCTAAAGATAAAACGTATAAAAGACTATGGATCAATAGTTTGAAGAAAG  
ATGTGATCCGTAGCGGTTTTCAAATTTGCAACCAGGAATGAATTACTATCCCTTTTATCA  
AGAAGCGCAAAAGAAAAACGAAATGATACACCAATCAGTGCAAAAAAAGATATAATGGGA  
GATAAGACGGTTCGTGTTCTGTGCTGACTTGCACCATATCATAAAATCGAAACAGCAAAG  
AATGGCGGAAACGTAAAAGAAGTTATGGAATAAGACTTAGAAGCAAACCTTAAGAGTGTG  
TTGATAGTGCAGTATCTTAAATTTTGTATAATAGGAATTGAAGTTAAATTAGATGCTAAAA  
ATTTGTAATTAAGAAGGAGTGATTACATGAACAAAAATATAAAATATTCTCAAACTTTTTA  
ACGAGTGAAAAAGTACTCAACCAATAATAAAACAATTGAATTTAAAAGAAACCGATACCG  
TTTACGAAATTGGAACAGGTAAAGGGCATTAAACGACGAAACTGGCTAAAATAAGTAAAC  
AGGTAACGTCTATTGAATTAGACAGTCATCTATTCAACTTATCGTCAGAAAAATTAAACT  
GAATACTCGTGCTACTTTAATTCACCAAGATATTCTACAGTTTCAATTCCTAACAAACAG  
AGGTATAAAATTGTTGGGAGTATTCTTACCATTAAAGCACACAAATTATTAAGGAGTGG  
TTTTTGAAAGCCATGCGTCTGACATCTATCTGATTGTTGAAGAAGGATTCTACAAGCGTA  
CCTTGGATATTACCGAACACTAGGGTTGCTCTTGCACACTCAAGTCTCGATTCAGCAAT  
TGCTTAAGCTGCCAGCGGAATGCTTTCATCCTAAACCAAAAGTAAACAGTGTCTTAATAA  
AACTTACCCGCCATACCACAGATGTTCCAGATAAATATTGGAAGCTATATACGTACTTTGT  
TTCAAATGGGTCAATCGAGAATATCGTCAACTGTTTACTAAAAATCAGTTTCATCAAGCA  
ATGAAACACGCCAAAGTAAACAATTTAAGTACCGTTACTTATGAGCAAGTATTGTCTATTT  
TTAATAGTTATCTATTATTTAACGGGAGGAAATAATTCTATGAGTCGCTTTTGTAAATTTG  
GAAAGTTACACGTTACTAAAGGGAATGTAGATAAATTATTAGGTATACTACTGACAGCTTC  
CAAGGAGCTAAAGAGGTCCCTAGCGCTCTTATCATGGGGAAGCTCGGATCATATGCAAG  
ACAAAATAAACTCGCAACAGCACTTGGAGAAATGGGACGAATCGAGAAAACCTCTTTAC  
GCTGGATTACATATCTAATAAAGCCGTAAGGAGACGGGTTCAAAAAGGTTTAAATAAAGG  
AGAAGCAATCAATGCATTAGCTAGAACTATATTTTTTGGACAACGTGGAGAATTTAGAGA  
ACGTGCTCTCCAAGACCAGTTACAAAGAGCTAGTGCACTAAACATAATTATTAACGCTAT  
AAGTGTGTGGAACACTGTATATATGAAAAAGCCGTAGAAGAATTAAGCAAGAGGAG  
AATTTAGAGAAGATTTAATGCCATATGCGTGGCCGTTAGGATGGGAACATATCAATTTTC  
TTGGAGAATACAAATTTGAAGGATTACATGACACTGGGCAAATGAATTTACGTCCTTTAC  
GTATAAAAGAGCCGTTTTATTCTTAATATAACGGCTCTTTTTATAGAAAAAATCCTTAGCG  
TGTTTTTTTTCCGAAATGCTGGCGGTACCCCAAGAATTAGAAATGAGTAGATCAAATTAT  
TCACGAATAGAATCAGGAAAATCAGATCCAACCATAAAAACACTAGAACAAATTGCAAG

***SUBSTITUTE SHEET (RULE 26)***

pT1MIL10 (cont.) Figure 1c (cont.)

TTAACTAACTCAACGCTAGTAGTGGATTTAATCCCAAATGAGCCAACAGAACCAGAGCCA  
GAAACAGAATCAGAACAAGTAACATTGGATTTAGAAATGGAAGAAGAAAAAAGCAATGAC  
TTCGTGTGAATAATGCACGAAATCGTTGCTTATTTTTTTTTTAAAAGCGGTATACTAGATAT  
AACGAAACAACGAACTGAATAGAAACGAAAAAAGAGCCATGACACATTTATAAAATGTTT  
GACGACATTTTATAAATGCATAGCCCGATAAGATTGCCAAACCAACGCTTATCAGTTAGT  
CAGATGAACTCTTCCCTCGTAAGAAGTTATTTAATTAACCTTGTGTTGAAGACGGTATATAA  
CCGTACTATCATTATATAGGGAAATCAGAGAGTTTTCAAGTATCTAAGCTACTGAATTTAA  
GAATTGTTAAGCAATCAATCGGAAATCGTTTGATTGCTTTTTTTGTATTCATTTATAGAAG  
GTGGAGTTTGTATGAATCATGATGAATGTAAACTTATATAAAAAATAGTTTATTGGAGAT  
AAGAAAATTAGCAAATATCTATACACTAGAAACGTTTAAGAAAGAGTTAGAAAAGAGAAAT  
ATCTACTTAGAAACAAAATCAGATAAGTATTTTTCTTCGGAGGGGGAAGATTATATATATA  
AGTTAATAGAAAATAACAAAATAATTTATTTCGATTAGTGGAAGAAAATTGACTTATAAAGG  
AAAAAATCTTTTTCAAACATGCAATATTGAAACAGTTGAATGAAAAAGCAAACCAAGTT  
AATTAACAACCTATTTTATAGGATTTATAGGAAAGGAGAACAGCTGAATGAATATCCCTT  
TTGTTGTAGAACTGTGCTTCATGACGGCTTGTTAAAGTACAAATTTAAAAATAGTAAAT  
TCGCTCAATCACTACCAAGCCAGGTAAAGCAAAGGGGCTATTTTTGCGTATCGCTCAAA  
ATCAAGCATGATTGGCGGTCTGTTGTTGTTCTGACTTCCGAGGAAGCGATTCAAGAAA  
ATCAAGATACATTTACACATTGGACACCCAACGTTTATCGTTATGGAACGTATGCAGACG  
AAAACCGTTCATACACGAAAGGACATTCTGAAAACAATTTAAGACAAATCAATACCTTCTT  
TATTGATTTTGATATTCACACGGCAAAAGAACTATTTTCAAGCAAGCGATATTTTAAACAACC  
GCTATTGATTTAGGTTTTATGCCTACTATGATTATCAAATCTGATAAAGGTTATCAAGCAT  
ATTTTGTTTTAGAAACGCCAGTCTATGTGACTTCAAATCAGAATTTAAATCTGTCAAAGC  
AGCCAAAATAATTTTCGCAAAATATCCGAGAATATTTTGGAAGTCTTTGCCAGTTGATCTA  
ACGTGTAATCATTTTGGTATTGCTCGCATACCAAGAACGGACAATGTAGAATTTTTTGATC  
CTAATTACCGTTATTCTTTCAAAGAATGGCAAGATTGGTCTTTCAAACAACAGATAATAA  
GGGCTTTACTCGTTCAAGTCTAACGGTTTTAAGCGGTACAGAAGGCAAAAAACAAGTAG  
ATGAACCCTGGTTTAATCTCTTATTGCACGAAACGAAATTTTCAGGAGAAAAGGGTTTAAT  
AGGGCGTAATAACGTCAATGTTTACCCTCTCTTTAGCCTACTTTAGTTTCAAGGCTATTCAATC  
GAAACGTGCGAATATAATATGTTTGAGTTTAATAATCGATTAGATCAACCCTTAGAAGAAA  
AAGAAGTAATCAAAATTGTTAGAAGTGCCTATTCAGAAAATCAAGGGGCTAATAGGG  
AATACATTACCATTCTTTGCAAAGCTTGGGTATCAAGTGATTTAACCAGTAAAGATTTATT  
TGTCGGTCAAGGGTGGTTTAAATTCAAGAAAAAAGAAGCGAACGTCAACGTGTTTCAATTT  
GTCAGAATGGAAAGAAGATTTAATGGCTTATATTAGCGAAAAAAGCGATGTATACAAGCC  
TTATTTAGTGACGACCAAAAAAGAGATTAGAGAAGTGCTAGGCATTCCTGAACGGACATT  
AGATAAATTGCTGAAGGTAAGGCGAATCAGGAAAATTTCTTTAAGATTAAACCAGG  
AAGAAATGGTGGCATTCAACTTGCTAGTGTTAAATCATTGTTGCTATCGATCATTAAAGTA  
AAAAAGAAGAAAAAGAAAGCTATATAAAGGCGCTGACAAATCTTTTGACTTAGAGCAT  
ACATTCATTCAAGAGACTTTAAACAAGCTAGCAGAACGCCCTAAAACGGACACACAACCTC  
GATTTGTTTAGCTATGATACAGGCTGAAAATAAAACCCGCACTATGCCATTACATTTATAT  
CTATGATACGTGTTTGTCTTTCTTTGCTGTTTAGCGAATGATTAGCAGAAATATACAGAG  
TAAGATTTTAATTAATTATTAGGGGGAGAAAGGAGAGAGTAGCCCGAAAACCTTTTAGTTGG  
CTTGGACTGAACGAAGTGAGGGAAAGGCTACTAAACGTGAGGGGGCAGTGAGAGCGA  
AGCGAACACTTGATTTTTTAATTTCTATCTTTTATAGGTCATTAGAGTATACTTATTTGTC  
CTATAAACTATTTAGCAGCATAATAGATTTATTGAATAGGTCATTTAAGTTGAGCATATTA  
GAGGAGGAAAATCTTGAGAAATATTTGAAGAACCCGATTACATGGATTGGATTAGTTCT  
TGTGGTTACGTGGTTTTTAATAAAAGTAGTGAATTTTGATTTTTGGTGTGTGTGCTTG  
TTGTTAGTATTTGCTAGTCAAAGTGATTAAATA

pT1TR5AH Figure 1c (cont.)

GAATTCGATTAAGTCATCTTACCTCTTTTATTAGTTTTTTCTTATAATCTAATGATAACATTT  
TTATAATTAATCTATAAACCATATCCCTCTTTGGAATCAAAATTTATTATCTACTCCTTTGTA  
GATATGTTATAATAACAAGTATCAGATCTGGGAGACCACAACGGTTTCCCCTAGAAATAA  
TTTTGTTAACTTTAGAAAGGAGATATACGCATGAAAAAAAAGATTATCTCAGCTATTTTAA  
TGTCTACAGTCATACTTTCTGCTGCAGCCCCGTTGTCAGGTGTTTACGCCCTGGTCCCTT  
CTCTTGGTGACCGGGAGAAGAGGGATAGCTTGTGTCCCCAAGGAAAGTATGTCCATTCT  
AAGAACAATTCCATCTGCTGCACCAAGTGCCACAAAGGAACCTACTTGGTGAGTGACTG  
TCCGAGCCCAGGGCGGGATACAGTCTGCAGGGAGTGTGAAAAGGGGCACCTTTACGGCT  
TCCCAGAATTACCTCAGGCAGTGTCTCAGTTGCAAGACATGTGCGAAAGAAATGTCCCA  
GGTGGAGATCTCTCCTTGCCAAGCTGACAAGGACACGGTGTGTGGCTGTAAGGAGAAC  
CAGTTCCAACGCTACCTGAGTGAGACACACTTCCAGTGCCTGGACTGCAGCCCCCTGCTT  
CAACGGCACCGTGACAATCCCCTGTAAGGAGACTCAGAACACCGTGTGTAACTGCCATG  
CAGGGTTCTTTCTGAGAGAAAGTGAGTGCCTCCCTTGCAAGCAACTGCAAGAAAAATGAG  
GAGTGTATGAAGTTGTGCCTACCTCCTCCGCTTGCAAATGTCACAAACCCCCAGGACTC  
AGGTACTGCGCATCATCATCATCATTAATAGACTAGTAGATCCGGCTGCTAACAAAG  
CCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTT  
GGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTGCTGAAAGGAGGAAGTATATCCGGATG  
ACCTGCAGGCAAGCTCTAGAATCGATACGATTTTGAAAGTGGAACAGATAAAAAAAGCA  
GTTTAAAATTGTTGCTGAACTTTTAAACAAGCAAATACAATCATTGTGCAACAGATAGC  
GACAGAGAAGGCGAAAACATTGCCTGGTGCATCATTATAAAGCAAATGCCTTTTCTAAA  
GATAAACGTATAAAAGACTATGGATCAATAGTTTAGAAAAAGATGTGATCCGTAGCGGT  
TTTCAAATTTGCAACCAGGAATGAATTACTATCCCTTTTATCAAGAAGCGCAAAAGAAAA  
ACGAAATGATACACCAATCAGTGCAAAAAAAGATATAATGGGAGATAAGACGGTTCGTGT  
TCGTGCTGACTTGCAACCATATCATAAAATCGAAACAGCAAAGAATGGCGGAAACGTAA  
AGAAGTTATGGAAATAAGACTTAGAAGCAAACCTAAGAGTGTGTTGATAGTGCAGTATCT  
TAAAATTTTGTATAATAGGAATTGAAGTTAAATTAGATGCTAAAAATTTGTAATTAAGAAGG  
AGTGATTACATGAACAAAAATATAAAATATTCTCAAAACTTTTTAACGAGTGAAAAAGTACT  
CAACCAAATAATAAAACAATTGAATTTAAAGAAACCGATACCGTTTACGAAATTGGAACA  
GGTAAAGGGCATTTAACGACGAAACTGGCTAAAATAAGTAAACAGGTAACGTCTATTGAA  
TTAGACAGTCATCTATTCAACTTATCGTCAGAAAAATTAAACTGAATACTCGTGTCACTT  
TAATTCACCAAGATATTCTACAGTTTCAATTCCCTAACAAACAGAGGTATAAAATTGTTGG  
GAGTATTCCTTACCATTTAAGCACACAAATTATTAAGAAAGTGGTTTTTGAAGCCATGCG  
TCTGACATCTATCTGATTGTTGAAGAAGGATTCTACAAGCGTACCTTGGATATTCACCGA  
ACACTAGGGTTGCTCTTGCACTCAAGTCTCGATTGAGCAATTGCTTAAGCTGCCAGC  
GGAATGCTTTCATCCTAAACCAAAGTAAACAGTGTCTTAATAAACTTACCCGCCATACC  
ACAGATGTTCCAGATAAATATTGGAAGCTATATACGTACTTTGTTTCAAATGGGTCAATC  
GAGAATATCGTCAACTGTTTACTAAAAATCAGTTTCATCAAGCAATGAAACACGCCAAAG  
TAAACAATTTAAGTACCGTTACTTATGAGCAAGTATTGTCTATTTTAAATAGTTATCTATTA  
TTTAAACGGGAGGAAATAATTCTATGAGTCGCTTTTGTAAATTTGGAAAGTTACACGTTACT  
AAAGGGGAATGTAGATAAATTATTAGGTATACTACTGACAGCTTCCAAGGAGCTAAAGAGG  
TCCCTAGCGCTCTTATCATGGGGAAGCTCGGATCATATGCAAGACAAAATAAACTCGCAA  
CAGCACTTGGAGAAATGGGACGAATCGAGAAAACCCCTCTTACGCTGGATTACATATCTA  
ATAAAGCCGTAAGGAGACGGGTTCAAAAAGGTTTAAATAAAGGAGAAGCAATCAATGCA  
TTAGCTAGAACTATATTTTTTGGACAACGTGGAGAATTTAGAGAACGTGCTCTCCAAGAC  
CAGTTACAAAGAGCTAGTGCACTAAACATAATTATTAACGCTATAAGTGTGTGGAACACT  
GTATATATGGAAAAAGCCGTAGAAGAATTAAAAGCAAGAGGAGAATTTAGAGAAGATTTA  
ATGCCATATGCGTGGCCGTTAGGATGGGAACATATCAATTTTCTTGGAGAATACAAATTT  
GAAGGATTACATGACACTGGGCAAATGAATTTACGTCCTTTACGTATAAAGAGCCGTTT  
TATTCTTAATATAACGGCTCTTTTATAGAAAAAATCCTTAGCGTGGTTTTTTTCCGAAATG

***SUBSTITUTE SHEET (RULE 26)***



pT1TR5AH (cont.) Figure 1c (cont.)

CTGGCGGTACCCCAAGAATTAGAAATGAGTAGATCAAATTATTCACGAATAGAATCAGGA  
AAATCAGATCCAACCATAAAAACACTAGAACAAATTGCAAAGTTAACTCAACGCTAG  
TAGTGGATTTAATCCCAAATGAGCCAACAGAACCCAGAGCCAGAAACAGAATCAGAACAA  
GTAACATTGGATTTAGAAATGGAAGAAGAAAAAGCAATGACTTCGTGTGAATAATGCAC  
GAAATCGTTGCTTATTTTTTTTTTAAAAGCGGTATACTAGATATAACGAAACAACGAACTGA  
ATAGAAACGAAAAAAGAGCCATGACACATTTATAAAATGTTTGACGACATTTTATAAATGC  
ATAGCCCGATAAGATTGCCAAACCAACGCTTATCAGTTAGTCAGATGAACTCTTCCCTCG  
TAAGAAGTTATTTAATTAACCTTTGTTTGAAGACGGTATATAACCGTACTATCATTATATAGG  
GAAATCAGAGAGTTTTCAAGTATCTAAGCTACTGAATTTAAGAATTGTTAAGCAATCAATC  
GGAAATCGTTTGATTGCTTTTTTTGTATTCAATTTATAGAAGGTGGAGTTTGTATGAATCAT  
GATGAATGTAAACTTTATATAAAAAATAGTTTATTGGAGATAAGAAAATTAGCAAATATCTA  
TACACTAGAAACGTTTAAGAAAGAGTTAGAAAAGAGAAAATATCTACTTAGAAACAAAATCA  
GATAAGTATTTTTCTTCGGAGGGGGAAGATTATATATATAAGTTAATAGAAAATAACAAAA  
TAATTTATTTCGATTAGTGGAAAAAAATTGACTTATAAAGGAAAAAAATCTTTTTCAAACAT  
GCAATATTGAAACAGTTGAATGAAAAAGCAAACCAAGTTAATTAACAACCTATTTTATAG  
GATTTATAGGAAAGGAGAACAGCTGAATGAATATCCCTTTTGTGTAGAAACTGTGCTTC  
ATGACGGCTTGTTAAAGTACAAATTTAAAAATAGTAAATTTCGCTCAATCACTACCAAGCC  
AGGTAAAAGCAAAGGGGCTATTTTTGCGTATCGCTCAAATCAAGCATGATTGGCGGTC  
GTGGTGTGTCTGACTTCCGAGGAAGCGATTCAAGAAAATCAAGATACATTTACACATT  
GGACACCCAACGTTTATCGTTATGGAACGTATGCAGACGAAAACCGTTCATACACGAAA  
GGACATTCTGAAAACAATTTAAGACAAATCAATACCTTCTTTATTGATTTTGATATTCACAC  
GGCAAAAGAACTATTTCAAGCAAGCGATATTTTAAACAACCGCTATTGATTTAGGTTTTATG  
CCTACTATGATTATCAAATCTGATAAAGGTTATCAAGCATATTTTGTTTTAGAAACGCCAG  
TCTATGTGACTTCAAATCAGAATTTAAATCTGTCAAAGCAGCCAAAATAATTCGCAAAA  
TATCCGAGAATATTTTGAAAGTCTTTGCCAGTTGATCTAACGTGTAATCATTTTGGTATT  
GCTCGCATACCAAGAACGGACAATGTAGAATTTTTTGATCCTAATTACCGTTATTCTTTCA  
AAGAATGGCAAGATTGGTCTTTCAAACAAACAGATAATAAGGGCTTTACTCGTTCAAGTC  
TAACGGTTTTAAGCGGTACAGAAGGCCAAAAACAAGTAGATGAACCCTGGTTTAATCTCT  
TATTGCACGAAACGAAATTTTCAGGAGAAAAGGGTTTAATAGGGCGTAATAACGTCATGT  
TTACCCTCTCTTTAGCCTACTTTAGTTTCAGGCTATTCAATCGAAACGTGCGAATATAATAT  
GTTTGAGTTTAATAATCGATTAGATCAACCCTTAGAAGAAAAAGAAGTAATCAAATTTGTT  
AGAAGTGCCTATTCAGAAACTATCAAGGGGCTAATAGGGAATACATTACCATTCTTTGC  
AAAGCTTGGGTATCAAGTGATTTAACCAGTAAAGATTTATTTGTCCGTCAAGGGTGGTTT  
AAATTCAGAAAAAAGAAGCGAACGTCAACGTGTTCAATTTGTCAGAATGGAAAGAAGAT  
TTAATGGCTTATATTAGCGAAAAAAGCGATGTATACAAGCCTTATTTAGTGACGACCAAAA  
AAGAGATTAGAGAAGTGCTAGGCATTCTGAACGGACATTAGATAAATTGCTGAAGGTA  
CTGAAGGCGAATCAGGAAATTTCTTTAAGATTAAACCAGGAAGAAATGGTGGCATTCAA  
CTTGCTAGTGTTAAATCATTGTTGCTATCGATCATTAAAGTAAAAAAGAAGAAAAAGAAA  
GCTATATAAAGGCGCTGACAAATCTTTTGACTTAGAGCATACATTCATTCAAGAGACTTT  
AAACAAGCTAGCAGAACGCCCTAAAACGGACACACAACCTCGATTTGTTTAGCTATGATAC  
AGGCTGAAAATAAAACCCGCACTATGCCATTACATTTATATCTATGATACGTGTTTGT  
TTCTTTGCTGTTTAGCGAATGATTAGCAGAAATATACAGAGTAAGATTTTAATTAATTATTA  
GGGGGAGAAGGAGAGAGTAGCCCGAAAACCTTTTAGTTGGCTTGGACTGAACGAAGTGA  
GGGAAAGGCTACTAAAACGTGAGGGGGCAGTGAGAGCGAAGCGAACACTTGATTTTTTA  
ATTTTCTATCTTTTATAGGTCATTAGAGTATACTTATTTGTCCTATAAACTATTTAGCAGCA  
TAATAGATTTATTGAATAGGTCATTTAAGTTGAGCATATTAGAGGAGGAAAATCTTGGAGA  
AATATTTGAAGAACCCGATTACATGGATTGGATTAGTTCTTGTGGTTACGTGGTTTTTAAC  
TAAAAGTAGTGAATTTTTGATTTTTGGTGTGTGTCTTGTGTTAGTATTTGCTAGTCAA  
AGTGATTAAATA

4/10




Figure 2

5/10




Figure 3

6/10




Figure 4

7/10




Figure 5




Figure 6

9/10




Figure 7

10/10




Figure 8



## SEQUENCE LISTING

<110> VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR BIOTECHNOL

<120> USE OF CYTOKINE-PRODUCING LACTOCOCCUS STRAIN TO TREAT  
COLITIS

<130> V1/002-V023

<140>

<141>

<150> 98203529.7

<151> 1998-10-20

<160> 8

<170> PatentIn Ver. 2.1

<210> 1

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer used  
for obtaining the plasmid pT1MIL10

<400> 1

cagtacagcc gggaagacaa t

21

<210> 2

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer used  
for obtaining the plasmid pT1MIL10

<400> 2

gcactagtta gcttttcatt ttgat

25

<210> 3

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer used  
for obtaining the plasmid pT1TR5AH

<400> 3

ctgggtccctt ctcttggtga c

21

<210> 4

<211> 53

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer used  
for obtaining the plasmid pT1TR5AH

<400> 4

ccactagtct attaatgatg atgatgatga tgcgcagtag ctgagtcctg ggg

53

<210> 5

<211> 5230

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: plasmid pTREX1

<400> 5

gaattcgatt aagtcattctt acctctttta ttagtTTTTT cttataatct aatgataaca 60  
tttttataat taatctataa accatatccc tctttggaat caaaatttat tatctactcc 120  
ttttagataa tgttataata caagtatcag atctgggaga ccacaacggt ttcccactag 180  
aaataatttt gtttaacttt agaaaggaga tatacgcagt caggatatct ctagaatgga 240  
tccggctgct aacaaagccc gaaaggaagc tgagttggct gctgccaccg ctgagcaata 300  
actagcataa ccccttgggg cctctaaacg ggtcttgagg ggTTTTTtgc tgaaaggagg 360  
aactatatcc ggatgacctg caggcaagct ctagaatcga tacgattttg aagtggcaac 420  
agataaaaaa aagcagttta aaattgttgc tgaactttta aaacaagcaa atacaatcat 480  
tgtcgcaaca gatagcgaca gagaaggcga aaacattgcc tggtcgatca ttcataaagc 540  
aaatgccttt tctaaagata aaacgtataa aagactatgg atcaatagtt tagaaaaaga 600  
tgtgatccgt agcggTTTTc aaaatttgca accaggaatg aattactatc ccttttatca 660  
agaagcgcaa aagaaaaacg aaatgatata ccaatcagtg caaaaaaaga tataatggga 720  
gataagacgg ttcgtgttcg tgctgacttg caccatatca taaaaatcga aacagcaaag 780  
aatggcgga aacgtaaaaga agttatggaa ataagactta gaagcaaact taagagtgtg 840  
ttgatagtgc agtatcttaa aattttgtat aataggaatt gaagttaaatt tagatgctaa 900  
aaatttgtaa ttaagaagga gtgattacat gaacaaaaat ataaaatatt ctcaaaactt 960

```

ttaaacgagt gaaaaagtac tcaaccaa atataaaaca ttgaatttaa aagaaaccga 1020
taccgtttac gaaattggaa caggtaaagg gcattttaacg acgaaactgg ctaaaataag 1080
taaacaggta acgtctattg aattagacag tcatctattc aacttatcgt cagaaaaatt 1140
aaaactgaat actcgtgtca ctttaattca ccaagatatt ctacagtttc aattccctaa 1200
caaacagagg tataaaattg ttgggagtat tctttacat ttaagcacac aaattattaa 1260
aaaagtgggt tttgaaagcc atgcgtctga catctatctg attggtgaag aaggattcta 1320
caagcgtacc ttggatattc accgaacact aggggttgctc ttgcacactc aagtctcgat 1380
tcagcaattg ctttaagctgc cagcggaaatg ctttcatcct aaaccaaag taaacagtgt 1440
cttaataaaa cttaccgcc ataccacaga tgttcagat aaatattgga agctatatac 1500
gtactttgtt tcaaaatggg tcaatcgaga atatcgtcaa ctggttacta aaaatcagtt 1560
tcatcaagca atgaaacacg ccaaagtaaa caatttaagt accgttactt atgagcaagt 1620
attgtctatt tttaatagtt atctattatt taacgggagg aaataattct atgagtcgct 1680
tttgtaaatt tggaaagtta cacgttacta aagggaatgt agataaatta ttaggtatac 1740
tactgacagc ttccaaggag cttaaagggt ccctagcgct cttatcatgg ggaagctcgg 1800
atcatatgca agacaaaata aactcgcaac agcacttgga gaaatgggac gaatcgagaa 1860
aaccctcttt acgctggatt acatatctaa taaagccgta aggagacggg ttcaaaaagg 1920
tttaataaaa ggagaagcaa tcaatgcatt agctagaact atattttttg gacaacgtgg 1980
agaatttaga gaacgtgctc tccaagacca gttacaaaga gctagtgcac taaacataat 2040
tattaacgct ataagtgtgt ggaacactgt atatatggaa aaagccgtag aagaattaaa 2100
agcaagagga gaatttagag aagatttaat gccatatgcg tggccgtag gatgggaaca 2160
tatcaatttt cttggagaat acaaatttga aggattacat gacactgggc aaatgaattt 2220
acgtccttta cgtataaaaag agccgtttta ttcttaatat aacggctctt tttatagaaa 2280
aaatccttag cgtggttttt ttccgaaatg ctggcggtac cccaagaatt agaaatgagt 2340
agatcaaatt attcacgaat agaatcagga aaatcagatc caaccataaa aacactagaa 2400
caaattgcaa agttaactaa ctcaacgcta gtagtggtat taatcccaaa tgagccaaca 2460
gaaccagagc cagaaacaga atcagaacaa gtaacattgg atttagaaat ggaagaagaa 2520
aaaagcaatg acttcgtgtg aataatgcac gaaatcgttg cttatttttt tttaaaagcg 2580
gtatactaga tataacgaaa caacgaactg aatagaaacg aaaaaagagc catgacacat 2640
ttataaaatg tttgacgaca ttttataaat gcatagcccg ataagattgc caaaccaacg 2700
cttatcagtt agtcagatga actcttcctt cgtaagaagt tatttaatta actttgtttg 2760
aagacggtat ataaccgtac tatcattata tagggaaatc agagagtttt caagtatcta 2820
agctactgaa tttagaatgt gtttaagcaat caatcggaat tcggttgatt gctttttttg 2880
tattcattta tagaagggtg agtttgtatg aatcatgatg aatgtaaaac ttatataaaa 2940
aatagtttat tggagataag aaaattagca aatatctata cactagaaac gtttaagaaa 3000
gagttagaaa agagaaatat ctacttagaa acaaaatcag ataagtattt ttcttcggag 3060
ggggaagatt atatataata gttaatagaa aataacaaaa taatttatc gattagtggg 3120
aaaaaattga cttataaagg aaaaaaatct ttttcaaac atgcaatatt gaaacagttg 3180
aatgaaaaag caaaccaagt taattaaaca acctatttta taggatttat aggaaaggag 3240
aacagctgaa tgaatatccc tttgttgta gaaactgtgc ttcatgacgg cttgttaaag 3300
tacaaattta aaaatagtaa aattcgctca atcactacca agccaggtaa aagcaaaggg 3360
gctatttttg cgtatcgctc aaaatcaagc atgattggcg gtcgtggtgt tgttctgact 3420
tccgaggaag cgattcaaga aaatcaagat acatttacac attggacacc caacgtttat 3480
cgttatggaa cgatgcaga cgaaaaccgt tcatacacga aaggacattc tgaaaacaat 3540
ttaagacaaa tcaatacctt ctttattgat tttgatattc acacggcaaa agaaactatt 3600
tcagcaagcg atattttaac aaccgctatt gatttaggtt ttatgcctac tatgattatc 3660
aaatctgata aaggttatca agcatatttt gttttagaaa cgccagtcta tgtgacttca 3720
aaatcagaat ttaaattctgt caaagcagcc aaaataattt cgcaaaatat ccgagaatat 3780
tttggaaggt ctttgccagt tgatctaacg tgtaatcatt ttggtattgc tcgcatacca 3840

```

```

agaacggaca atgtagaatt ttttgatcct aattaccgtt attctttcaa agaattggcaa 3900
gattgggtcct tcaaacaaac agataataag ggctttactc gttcaagtct aacgggtttta 3960
agcgggtacag aaggcaaaaa acaagtagat gaaccctggt ttaatctctt attgcacgaa 4020
acgaaatctt caggagaaaa gggtttaata gggcgtaata acgtcatgtt taccctctct 4080
ttagcctact ttagttcagg ctattcaatc gaaacgtgcg aatataatat gtttgagttt 4140
aataatcgat tagatcaacc cttagaagaa aaagaagtaa tcaaaattgt tagaagtgcc 4200
tattcagaaa actatcaagg ggctaataag gaatacatta ccattctttg caaagcttg 4260
gtatcaagtg atttaaccag taaagattta ttgtccgtc aagggtggtt taaattcaag 4320
aaaaaaagaa ggaacgtca acgtgttcac ttgtcagaat ggaaagaaga tttaattggct 4380
tatattagcg aaaaaagcga tgtatacaag ccttatttag tgacgaccaa aaaagagatt 4440
agagaagtgc taggcattcc tgaacggaca ttagataaat tgctgaaggc actgaaggcg 4500
aatcaggaaa ttttcttta gattaaacca ggaagaaatg gtggcattca acttgctagt 4560
gttaaatcat tgttgctatc gatcattaaa gtaaaaaaag aagaaaaaga aagctatata 4620
aaggcgctga caaattcttt tgacttagag catacattca ttcaagagac tttaacaag 4680
ctagcagaac gccctaaaac ggacacacaa ctcgatttgt ttagctatga tacaggctga 4740
aaataaaaacc cgcactatgc cattacattt atatctatga tacgtgtttg ttttttcttt 4800
gctgttttagc gaatgattag cagaaatata cagagtaaga tttaatttaa ttattagggg 4860
gagaaggaga gagtagcccg aaaactttta gttggcttg actgaacgaa gtgagggaaa 4920
ggctactaaa acgtcgaggg gcagtgagag cgaagcgaac acttgatttt ttaattttct 4980
atcttttata ggtcattaga gtatacttat ttgtcctata aactatttag cagcataata 5040
gatttattga ataggtcatt taagttgagc atattagagg aggaaaatct tggagaaata 5100
tttgaagaac cagattacat ggattggatt agttcttggt gttacgtggt tttaactaa 5160
aagtagtgaa tttttgattt ttggtgtgtg tgtcttggtt ttagtatttg ctagtcaaag 5220
tgattaaata                                     5230

```

<210> 6

<211> 5906

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: plasmid pTlNX

<400> 6

```

gaattcgatt aagtcattctt acctctttta ttagtttttt cttataatct aatgataaca 60
tttttataat taatctataa accatatccc tctttggaat caaaatttat tatctactcc 120
ttttagataa tgttataata caagtatcag atctgggaga ccacaacggt ttccactag 180
aaataatctt gtttaacttt agaaaggaga tatacgcatt aaaaaaaga ttatctcagc 240
tattttaatg tctacagtca tactttctgc tgcagcccg ttgtcaggtg ttacgccc 300
cgacggatcc aaaagaggaa gacaataaca agcctggcaa agaagacaat aacaagcctg 360
gcaaagaaga caataacaag cctggcaaag aagacaacaa caagcctggc aaagaagaca 420
acaacaagcc tggtaaagaa gacaacaaca agcctggcaa agaagacggc aacaagcctg 480
gtaaagaaga caacaaaaaa cctggtaaag aagatggcaa caagcctggt aaagaagaca 540
acaaaaaac tggtaaagaa gacggcaaca agcctggcaa agaagatggc acaaacctg 600
gtaaagaaga tggtaacgga gtacatgtcg ttaaacctgg tgatacagta aatgacattg 660
caaaagcaaa cggcactact gctgacaaaa ttgctgcaga taacaaatta gctgataaaa 720
acatgatcaa acctggtcaa gaacttggtt ttgataagaa gcaaccagca aacctgacg 780

```

```

atgctaacaa agctcaagca ttaccagaaa ctggcgaaga aaatccattc atcgggtacaa 840
ctgtatttgg tggattatca ttagccttag gtgcagcggt attagctgga cgtcgtcgcg 900
aactataact agtagatccg gctgctaaca aagcccga aaagctgag ttggctgctg 960
ccaccgctga gcaataacta gcataacccc ttggggcctc taaacgggtc ttgaggggtt 1020
ttttgctgaa aggaggaact atatccgat gacctgcagg caagctctag aatcgatacg 1080
atattgaagt ggcaacagat aaaaaaaagc agtttaaaat tgttgctgaa cttttaaaac 1140
aagcaaatac aatcattgtc gcaacagata gcgacagaga aggcgaaaac attgcctggt 1200
cgatcattca taaagcaaat gccttttcta aagataaaac gtataaaaga ctatggatca 1260
atagttttaga aaaagatgtg atccgtagcg gttttcaaaa ttgcaacca ggaatgaatt 1320
actatccctt ttatcaagaa gcgcaaaaaga aaaacgaaat gatacaccaa tcagtgc aaa 1380
aaaagatata atgggagata agacggttcg tgttcgtgct gacttgcacc atatcataaa 1440
aatcgaaaca gcaagaatg gcggaacgt aaaagaagt atggaaataa gacttagaag 1500
caaacttaag agtgtgttga tagtgcagta tcttaaaatt ttgtataata ggaattgaag 1560
ttaaattaga tgctaaaaat ttgtaattaa gaaggagtga ttacatgaac aaaaatataa 1620
aatattctca aaacttttta acgagtga aaagtactca ccaaataata aaacaattga 1680
atttaaaaga aaccgatacc gtttacgaaa ttggaacagg taaagggcat ttaacgacga 1740
aactggctaa aataagtaaa caggtaacgt ctattgaatt agacagtcatt ctattcaact 1800
tatcgtcaga aaaattaaaa ctgaatactc gtgtcacttt aattcaccaa gatattctac 1860
agtttcaatt ccctaacaaa cagaggtata aaattgttgg gagtattcct taccatttaa 1920
gcacacaaat tattaaaaaa gtggtttttg aaagccatgc gtctgacatc tatctgattg 1980
ttgaagaagg attctacaag cgtacccttg atattcaccg aacactaggg ttgctcttgc 2040
acactcaagt ctcgattcag caattgctta agctgccagc ggaatgcttt catcctaaac 2100
caaaagtaaa cagtgtctta ataaaactta cccgccatac cacagatgtt ccagataaat 2160
attggaagct atatacgtac tttgtttcaa aatgggtcaa tcgagaatat cgtcaactgt 2220
ttactaaaaa tcagtttcat caagcaatga aacacgcaa agtaaacaat ttaagtaccg 2280
ttacttatga gcaagtattg tctattttta atagttatct attatttaac gggaggaaat 2340
aattctatga gtcgcttttg taaatttggg aagttacacg ttactaaagg gaatgtagat 2400
aaattattag gtatactact gacagcttcc aaggagctaa agaggtccct agcgtcttta 2460
tcattgggaa gctcggatca tatgcaagac aaaataaact cgcaacagca cttggagaaa 2520
tgggacgaat cgagaaaacc ctctttacgc tggattacat atctaataaa gccgtaagga 2580
gacgggttca aaaaggttta aataaaggag aagcaatcaa tgcattagct agaactatat 2640
tttttggaac acgtggagaa tttagagaac gtgctctcca agaccagtta caaagagcta 2700
gtgcactaaa cataattatt aacgctataa gtgtgtggaa cactgtatat atggaaaaag 2760
ccgtagaaga attaaaagca agaggagaat ttagagaaga ttaaatgcca tatgcgtggc 2820
cgtaggatg ggaacatata aattttcttg gagaatacaa atttgaagga ttacatgaca 2880
ctgggcaaat gaatttacgt cctttacgta taaaagagcc gttttattct taatataacg 2940
gctcttttta tagaaaaaat ccttagcgtg gtttttttcc gaaatgctgg cggtaaccca 3000
agaattagaa atgagtagat caaattattc acgaatagaa tcaggaaaat cagatccaac 3060
cataaaaaa ctagaacaaa ttgcaaagtt aactaactca acgctagtag tggatttaaat 3120
cccaaatgag ccaacagaac cagagccaga aacagaatca gaacaagtaa cattggattt 3180
agaaatggaa gaagaaaaaa gcaatgactt cgtgtgaata atgcacgaaa tcgttgctta 3240
ttttttttta aaagcgggtat actagatata acgaaacaac gaactgaata gaaacgaaaa 3300
aagagccatg acacatttat aaaatgtttg acgacatttt ataaatgcat agcccgataa 3360
gattgcaaaa ccaacgctta tcagttagtc agatgaactc ttccctcgta agaagttatt 3420
taattaactt tgtttgaaga cggatatata ccgtactatc attatatagg gaaatcagag 3480
agttttcaag tatctaagct actgaattta agaattgtta agcaatcaat cggaaatcgt 3540
ttgattgctt tttttgtatt catttataga aggtggagtt tgtatgaatc atgatgaatg 3600
taaaacttat ataaaaaata gtttatttga gataagaaaa ttagcaaata tctatacact 3660

```

```

agaaacgttt aagaaagagt tagaaaagag aaatatctac ttagaaacaa aatcagataa 3720
gtatttttct tcggaggggg aagattatat atataagtta atagaaaata acaaaataat 3780
ttattcgatt agtggaaaaa aattgactta taaaggaaaa aaatcttttt caaaacatgc 3840
aatattgaaa cagttgaatg aaaaagcaaa ccaagttaat taaacaacct attttatagg 3900
atttatagga aaggagaaca gctgaatgaa tatccctttt gttgtagaaa ctgtgcttca 3960
tgacggcttg ttaaagtaca aatttaaaaa tagtaaaatt cgctcaatca ctaccaagcc 4020
aggtaaaagc aaaggggcta tttttgcgta tcgctcaaaa tcaagcatga ttggcggtcg 4080
tggtgttggt ctgacttccg aggaagcgat tcaagaaaat caagatacat ttacacattg 4140
gacacccaac gtttatcggt atggaacgta tgcagacgaa aaccgttcat acacgaaagg 4200
acattctgaa aacaatttaa gacaaatcaa taccttcttt attgattttg atattcacac 4260
ggcaaaagaa actatttcag caagcgatat tttaacaacc gctattgatt taggttttat 4320
gcctactatg attatcaa atctgataaagg ttatcaagca tattttgttt tagaaacgcc 4380
agtctatgtg acttcaaaaat cagaatttaa atctgtcaaa gcagccaaaa taatttcgca 4440
aaatatccga gaatattttg gaaagtcttt gccagttgat ctaacgtgta atcatttttg 4500
tattgctcgc ataccaagaa cggacaatgt agaatttttt gatcctaatt accgttattc 4560
tttcaaagaa tggcaagatt ggtctttcaa acaaacagat aataagggct ttactcgttc 4620
aagtctaacg gttttaagcg gtacagaagg caaaaaacaa gtagatgaac cctggtttaa 4680
tctcttattg cacgaaacga aattttcagg agaaaagggg ttaatagggc gtaataacgt 4740
catgtttacc ctctcttttag cctacttttag ttcaggctat tcaatcgaaa cgtgcgaata 4800
taatattgtt gagtttaata atcgattaga tcaaccctta gaagaaaaag aagtaatcaa 4860
aattgttaga agtgcctatt cagaaaacta tcaaggggct aataggggaat acattaccat 4920
tctttgcaaa gcttgggtat caagtgattt aaccagtaaa gatttatttg tccgtcaagg 4980
gtggttttaa ttcaagaaaa aaagaagcga acgtcaacgt gttcatttgt cagaatggaa 5040
agaagattta atggcttata ttagcgaaaa aagcgatgta tacaagcctt atttagtgac 5100
gacaaaaaaa gagattagag aagtgc tagg cattcctgaa cggacattag ataaattgct 5160
gaaggtagtg aaggcgaatc aggaattttt cttaagatt aaaccaggaa gaaatggtgg 5220
cattcaactt gctagtgtta aatcattgtt gctatcgatc attaaagtaa aaaaagaaga 5280
aaaagaaagc tatataaagg cgctgacaaa ttcttttgac ttagagcata cattcattca 5340
agagacttta aacaagctag cagaacgccc taaaacggac acacaactcg atttgtttag 5400
ctatgatata ggctgaaaat aaaacccgca ctatgccatt acattttatat ctatgatagc 5460
tgtttgtttt ttctttgctg ttttagcgaat gattagcaga aatatacaga gtaagatttt 5520
aattaattat tagggggaga aggagagagt agcccgaaaa ctttttagttg gcttggactg 5580
aacgaagtga gggaaaggct actaaaacgt cgaggggcag tgagagcgaa gcgaacactt 5640
gattttttta ttttctatct tttataggtc attagagtat acttatttgt cctataaact 5700
atttagcagc ataatagatt tattgaatag gtcatttaag ttgagcatat tagaggagga 5760
aaatcttgga gaaatatatt aagaaccgga ttacatggat tggattagtt cttgtggtta 5820
cgtggttttt aactaaaagt agtgaatttt tgatttttgg tgtgtgtgtc ttgttgtag 5880
tatttgctag tcaaagtgat taaata 5906

```

<210> 7

<211> 5770

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: plasmid  
pT1MIL10

&lt;400&gt; 7

```

gaattcgatt aagtcacatt acctctttta ttagtTTTTT cttataatct aatgataaca 60
TTTTTaat taatctataa accatatccc tctttggaat caaaatttat tatctactcc 120
ttttagata tgttataata caagtatcag atctgggaga ccacaacggt ttcccactag 180
aaataatttt gtttaacttt agaaaggaga tatacgcatt aaaaaaaga ttatctcagc 240
tattttaatg tctacagtca tactttctgc tgcagccccg ttgtcaggtg tttacgcccc 300
gtacagccgg gaagacaata actgcacca cttcccagtc ggccagagcc acatgctcct 360
agagctgagg actgccttca gccaggtgaa gactttcttt caaacaagg accagctgga 420
caacatactg ctaaccgact ccttaattga ggactttaag ggttacttgg gttgccaagc 480
cttatcgga atgatccagt ttacctggt agaagtgatg cccagggcag agaagcatgg 540
cccagaaatc aaggagcatt tgaattccct gggtgagaag ctgaagacc tcaggatgag 600
gctgaggcgc tgtcatcgat ttctccctg tgaataaag agcaaggcag tggagcaggt 660
gaagagtgat ttaataaagc tccaagacca aggtgtctac aaggccatga atgaatttga 720
catcttcac aactgcatag aagcatacat gatgatcaaa atgaaaagct aactagtaga 780
tccggctgct aacaaagccc gaaaggaagc tgagttggct gctgccaccg ctgagcaata 840
actagcataa ccccttgggg cctctaaacg ggtcttgagg ggttttttgc tgaaaggagg 900
aactatatcc ggatgacctg caggcaagct ctagaatcga tacgattttg aagtggcaac 960
agataaaaaa aagcagttta aaattgttgc tgaactttta aaacaagcaa atacaatcat 1020
tgtcgcaaca gatagcgaca gagaaggcga aaacattgcc tggtcgatca ttcataaagc 1080
aaatgccttt tctaaagata aaacgtataa aagactatgg atcaatagtt tagaaaaga 1140
tgtgatccgt agcggttttc aaaatttgca accaggaatg aattactatc ccttttatca 1200
agaagcgcaa aagaaaaacg aaatgataca ccaatcagtg caaaaaaaga tataatggga 1260
gataagacgg ttctgtgtcg tgctgacttg caccatatca taaaaatcga aacagcaaag 1320
aatggcgga acgtaaaaga agttatggaa ataagactta gaagcaaact taagagtgtg 1380
ttgatagtgc agtatcttaa aattttgtat aataggaatt gaagttaaatt tagatgctaa 1440
aaatttgtaa ttaagaagga gtgattacat gaacaaaaat ataaaatatt ctcaaaactt 1500
tttaacgagt gaaaaagtac tcaaccaa ataaaaacaa ttgaatttaa aagaaaccga 1560
taccgtttac gaaattggaa caggtaaagg gcatttaacg acgaaactgg ctaaaataag 1620
taaacaggtg acgtctattg aattagacag tcatctattc aacttatcgt cagaaaaatt 1680
aaaactgaat actcgtgtca ctttaattca ccaagatatt ctacagtttc aattccctaa 1740
caaacagagg tataaaattg ttgggagtat tccttaccat ttaagcacac aaattattaa 1800
aaaagtgggt tttgaaagcc atgcgtctga catctatctg attgttgaag aaggattcta 1860
caagcgtacc ttggatattc accgaacact aggggtgctc ttgcacactc aagtctcgat 1920
tcagcaattg cttaaagctgc cagcggaatg ctttcatcct aaaccaaag taaacagtgt 1980
cttaataaaa cttaccgcc ataccacaga tgttcagat aaatattgga agctatatac 2040
gtactttgtt tcaaatggg tcaatcgaga atatcgtcaa ctgtttacta aaatcagtt 2100
tcatcaagca atgaaacacg ccaaagtaaa caatttaagt accgttactt atgagcaagt 2160
attgtctatt ttaaatagtt atctattatt taacgggagg aaataattct atgagtcgct 2220
tttgtaaatt tggaaagtta cacgttacta aagggaatgt agataaatta ttaggtatac 2280
tactgacagc ttccaaggag ctaaagaggt ccctagcgct cttatcatgg ggaagctcgg 2340
atcatatgca agacaaaata aactcgcaac agcacttgga gaaatgggac gaatcgagaa 2400
aacctcttt acgctggatt acatatctaa taaagccgta aggagacggg ttcaaaaagg 2460
tttaataaaa ggagaagcaa tcaatgcatt agctagaact atatttttg gacaacgtgg 2520
agaatttaga gaacgtgctc tccaagacca gttacaaaga gctagtgcac taaacataat 2580
tattaacgct ataagtgtgt ggaacactgt atatatggaa aaagccgtag aagaattaaa 2640
agcaagagga gaatttagag aagattta atgccatgagc tggccgtag gatgggaaca 2700
tatcaatttt cttggagaat acaaatttga aggattacat gacactgggc aaatgaattt 2760

```

```

acgtccttta cgtataaaag agccggtttta ttcttaatat aacggctcct tttatagaaa 2820
aaatccttag cgtgggttttt ttccgaaatg ctggcggtac cccaagaatt agaaatgagt 2880
agatcaaatt attcacgaat agaatacagga aaatcagatc caaccataaa aacactagaa 2940
caaattgcaa agttaactaa ctcaacgcta gtagtggtatt taatcccaaa tgagccaaca 3000
gaaccagagc cagaaacaga atcagaacaa gtaacattgg atttagaaat ggaagaagaa 3060
aaaagcaatg acttcgtgtg aataatgcac gaaatcgttg cttatttttt tttaaaagcg 3120
gtatactaga tataacgaaa caacgaactg aatagaaacg aaaaaagagc catgacacat 3180
ttataaaatg tttgacgaca ttttataaat gcatagcccg ataagattgc caaaccaacg 3240
cttatcagtt agtcagatga actcttcctt cgtaagaagt tatttaatta actttgtttg 3300
aagacggtat ataaccgtac tatcattata tagggaaatc agagagtttt caagtatcta 3360
agctactgaa ttaagaatt gttaagcaat caatcgaaa tcgttttgatt gctttttttg 3420
tattcattta tagaagggtg agtttgatg aatcatgatg aatgtaaaac ttatataaaa 3480
aatagtttat tggagataag aaaattagca aatatctata cactagaaac gtttaagaaa 3540
gagttagaaa agagaaatat ctacttagaa acaaaatcag ataagtattt ttcttcggag 3600
ggggaagatt atatatataa gttaatagaa aataacaaaa taattttattc gattagtggg 3660
aaaaaattga cttataaagg aaaaaaatct ttttcaaac atgcaatatt gaaacagttg 3720
aatgaaaaag caaccaagt taattaaaca acctatttta taggatttat aggaaaggag 3780
aacagctgaa tgaatatccc ttttgttgta gaaactgtgc ttcattgacg cttgttaaag 3840
tacaaattta aaaatagtaa aattcgctca atcactacca agccaggtaa aagcaaaggg 3900
gctatttttg cgtatcgctc aaaatcaagc atgattggcg gtcgtggtgt tgttctgact 3960
tccgaggaag cgattcaaga aaatcaagat acatttacac attggacacc caacgtttat 4020
cgttatggaa cgtatgcaga cgaaaaccgt tcatacacga aaggacattc tgaaaacaat 4080
ttaagacaaa tcaatacctt ctttattgat ttgatattc acacggcaaa agaaactatt 4140
tcagcaagcg atattttaac aaccgctatt gatttaggtt ttatgcctac tatgattatc 4200
aaatctgata aaggttatca agcatatttt gttttagaaa cgccagtcta tgtgacttca 4260
aaatcagaat ttaaatctgt caaagcagcc aaaataattt cgcaaaatat ccgagaatat 4320
tttggaaggt ctttgccagt tgatctaacg tgtaatcatt ttggtattgc tcgcatacca 4380
agaacggaca atgtagaatt ttttgatcct aattaccgtt attctttcaa agaattggca 4440
gattggtcct tcaaacaaac agataataag ggctttactc gttcaagtct aacggtttta 4500
agcggtagac aaggcaaaaa acaagtagat gaaccctggg ttaatctctt attgcacgaa 4560
acgaaatttt caggagaaaa gggtttaata gggcgtaata acgtcatgtt taccctctct 4620
ttagcctact ttagttcagg ctattcaatc gaaacgtgcg aatataatat gtttgagttt 4680
aataatcgat tagatcaacc cttagaagaa aaagaagtaa tcaaaattgt tagaagtgcc 4740
tattcagaaa actatcaagg ggctaataag gaatacatta ccattctttg caaagcttgg 4800
gtatcaagtg atttaaccag taaagattta ttgtccgtc aagggtggtt taaattcaag 4860
aaaaaaagaa gcgaacgtca acgtgttcat ttgtcagaat ggaaagaaga tttaatggct 4920
tatattagcg aaaaaagcga tgtatacaag ccttatttag tgacgaccaa aaaagagatt 4980
agagaagtgc taggcattcc tgaacggaca ttagataaat tgctgaagggt actgaaggcg 5040
aatcaggaaa ttttctttta gattaaacca ggaagaaatg gtggcattca acttgctagt 5100
gttaaatcat tgttgctatc gatcattaaa gtaaaaaaag aagaaaaaga aagctatata 5160
aaggcgctga caaattcttt tgacttagag catacattca ttcaagagac tttaaacaag 5220
ctagcagaac gccctaaaac ggacacacaa ctcgatttgt ttagctatga tacaggctga 5280
aaataaaacc cgcactatgc cattacattt atatctatga tacgtgtttg tttttctttt 5340
gctgttttagc gaatgattag cagaaatata cagagtaaga ttttaattaa ttattagggg 5400
gagaaggaga gagtagcccg aaaactttta gttggcttgg actgaacgaa gtgagggaaa 5460
ggctactaaa acgtcgaggg gcagtgaag cgaagcgaac acttgatttt ttaattttct 5520
atcttttata ggtcattaga gtatacttat ttgtcctata aactatttag cagcataata 5580
gatttattga ataggtcatt taagttgagc atattagagg aggaaaatct tggagaaata 5640

```



tttgaagaac ccgattacat ggattggatt agttcttgtg gttacgtggt ttttaactaa 5700  
aagtagtgaa tttttgattt ttggtgtgtg tgtcttggtg ttagtatttg ctagtcaaag 5760  
tgattaaata 5770

<210> 8

<211> 5870

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: plasmid

pT1TR5AH

<400> 8

gaattcgatt aagtcattctt acctctttta ttagtttttt cttataatct aatgataaca 60  
tttttataat taatctataa accatatccc tctttggaat caaaatttat tatctactcc 120  
ttttagataa tgttataata caagtatcag atctgggaga ccacaacggt ttcccactag 180  
aaataatttt gtttaacttt agaaaggaga tatacgcgag aaaaaaaga ttatctcagc 240  
tattttaatg tctacagtca tactttctgc tgcagccccg ttgtcagggtg ttacgcccct 300  
ggccccctct cttggtgacc gggagaagag ggatagcttg tgtccccaag gaaagtatgt 360  
ccattctaag aacaattcca tctgctgcac caagtgccac aaaggaacct acttggtgag 420  
tgactgtccg agcccagggc gggatacagt ctgcaggagg tgtgaaaagg gcacctttac 480  
ggcttcccag aattacctca ggcagtgtct cagttgcaag acatgtcgga aagaaatgtc 540  
ccagggtggag atctctcctt gccaaagtga caaggacacg gtgtgtggct gtaaggagaa 600  
ccagttccaa cgctacctga gtgagacaca cttccagtgc gtggactgca gcccctgctt 660  
caacggcacc gtgacaatcc cctgtaagga gactcagaac accgtgtgta actgccatgc 720  
agggttcttt ctgagagaaa gtgagtgcgt cccttgacgc cactgcaaga aaaatgagga 780  
gtgtatgaag ttgtgcctac ctccctccgt tgc aaatgtc acaaaccccc aggactcagg 840  
tactgcgcat catcatcatc atcattaata gactagtaga tccggctgct aacaaagccc 900  
gaaaggaagc tgagttggct gctgccaccg ctgagcaata actagcataa ccccttgggg 960  
cctctaaacg ggtcttgagg ggttttttgc tgaaaggagg aactatatcc ggatgacctg 1020  
caggcaagct ctagaatcga tacgattttg aagtggcaac agataaaaaa aagcagttta 1080  
aaattgttgc tgaactttta aaacaagcaa atacaatcat tgtcgcaaca gatagcgaca 1140  
gagaaggcga aaacattgcc tggctgatca ttcataaagc aaatgccttt tctaaagata 1200  
aaacgtataa aagactatgg atcaatagtt tagaaaaaga tgtgatccgt agcgggtttc 1260  
aaaatttgca accaggaatg aattactatc ccttttatca agaagcgcaa aagaaaaacg 1320  
aaatgataca ccaatcagtg caaaaaaaga tataatggga gataagacgg ttcgtgttcg 1380  
tgctgacttg caccatatca taaaaatcga aacagcaaag aatggcgga aacgtaaaaga 1440  
agttatggaa ataagactta gaagcaaact taagagtgtg ttgatagtgc agtatcttaa 1500  
aattttgtat aataggaatt gaagttaaatt tagatgctaa aaatttgtaa ttaagaagga 1560  
gtgattacat gaacaaaaat ataaaatatt ctcaaaactt tttaacgagt gaaaaagtac 1620  
tcaaccaaata aataaaacaa ttgaatttaa aagaaaccga taccgtttac gaaattggaa 1680  
caggtaaagg gcatttaacg acgaaactgg ctaaaataag taaacaggta acgtctattg 1740  
aattagacag tcatctattc aacttatcgt cagaaaaatt aaaactgaat actcgtgtca 1800  
ctttaattca ccaagatatt ctacagtttc aattccctaa caaacagagg tataaaattg 1860  
ttgggagtat tcttaccat ttaagcacac aaattattaa aaaagtgggt tttgaaagcc 1920  
atgcgtctga catctatctg attgttgaag aaggattcta caagcgtacc ttggatattc 1980

accgaacact agggttgctc ttgcacactc aagtctcgat tcagcaattg cttaaagctgc 2040  
cagcggaatg ctttcacctt aaaccaaag taaacagtgt ctttaataaaa cttaccgcc 2100  
ataccacaga tggtccagat aaatattgga agctatatac gtactttggt tcaaaatggg 2160  
tcaatcgaga atatcgtaa ctgtttacta aaaatcagtt tcatcaagca atgaaacacg 2220  
ccaaagtaaa caatttaagt accgttactt atgagcaagt attgtctatt tttaatagtt 2280  
atctattatt taacgggagg aaataattct atgagtcgct tttgtaaatt tggaaagtta 2340  
cacgttacta aagggaatgt agataaatta ttaggtatac tactgacagc ttccaaggag 2400  
ctaaagaggt ccttagcgct cttatcatgg ggaagctcgg atcatatgca agacaaaata 2460  
aactcgcaac agcacttgga gaaatgggac gaatcgagaa aaccctcttt acgctggatt 2520  
acatatctaa taaagccgta aggagacggg ttcaaaaagg tttaaataaa ggagaagcaa 2580  
tcaatgcatt agctagaact atattttttg gacaacgtgg agaatttaga gaacgtgctc 2640  
tccaagacca gttacaaaga gctagtgcac taaacataat tattaacgct ataagtgtgt 2700  
ggaacactgt atatatggaa aaagccgtag aagaattaaa agcaagagga gaatttagag 2760  
aagatttaaat gccatatgcg tggccgttag gatgggaaca tatcaatttt cttggagaat 2820  
acaaatttga aggattacat gacactgggc aaatgaattt acgtccttta cgtataaaaag 2880  
agccgtttta ttcttaatat aacggctctt tttatagaaa aaatccttag cgtgggtttt 2940  
ttccgaaatg ctggcgttac cccaagaatt agaatgagt agatcaaatt attcacgaat 3000  
agaatcagga aaatcagatc caaccataaa aacactagaa caaattgcaa agttaactaa 3060  
ctcaacgcta gtagtggtt taatcccaa tgagccaaca gaaccagagc cagaaacaga 3120  
atcagaacaa gtaacattgg atttagaaat ggaagaagaa aaaagcaatg acttcgtgtg 3180  
aataatgcac gaaatcgttg cttatttttt tttaaaagcg gtatactaga tataacgaaa 3240  
caacgaactg aatagaaacg aaaaaagagc catgacacat ttataaaatg tttgacgaca 3300  
ttttataaat gcatagcccg ataagattgc caaaccaacg cttatcagtt agtcagatga 3360  
actcttccct cgtaagaagt tatttaatta actttgtttg aagacggtat ataaccgtac 3420  
tatcattata tagggaaatc agagagtttt caagtatcta agctactgaa ttttaagaatt 3480  
gttaagcaat caatcgaaa tcgtttgatt gctttttttg tattcattta tagaagggtg 3540  
agtttgatg aatcatgatg aatgtaaaac ttatataaaa aatagtttat tggagataag 3600  
aaaattagca aatatctata cactagaaac gttaagaaa gagttagaaa agagaaatat 3660  
ctacttagaa acaaaatcag ataagtattt ttcttcggag ggggaagatt atatatataa 3720  
gttaatagaa aataacaaaa taattttattc gattagtggg aaaaaattga cttataaagg 3780  
aaaaaaatct ttttcaaac atgcaatatt gaaacagttg aatgaaaaag caaaccaagt 3840  
taattaaaca acctatttta taggatttat aggaaaggag aacagctgaa tgaatatccc 3900  
ttttgttgta gaaactgtgc ttcatgacgg cttgttaaag taaaaattta aaaatagtaa 3960  
aattcgctca atcactacca agccaggtaa aagcaaaggg gctatttttg cgtatcgctc 4020  
aaaatcaagc atgattggcg gtcgtggtgt tgttctgact tccgaggaag cgattcaaga 4080  
aaatcaagat acatttacac attggacacc caacgtttat cgttatggaa cgtatgcaga 4140  
cgaaaaccgt tcatacacga aaggacattc tgaaaacaat ttaagacaaa tcaatacctt 4200  
ctttattgat ttgatattc acacggcaaa agaaactatt tcagcaagcg atattttaac 4260  
aaccgctatt gatttaggtt ttatgcctac tatgattatc aaatctgata aaggttatca 4320  
agcatatttt gtttagaaa cgccagtcta tgtgacttca aaatcagaat ttaaactctgt 4380  
caaagcagcc aaaataattt cgcaaaatat ccgagaatat tttggaaagt ctttgccagt 4440  
tgatctaacg tgtaatcatt ttggtattgc tcgcatacca agaacggaca atgtagaatt 4500  
ttttgatcct aattaccgtt attctttcaa agaatggcaa gattggtctt tcaaacaaac 4560  
agataataag ggctttactc gttcaagtct aacggtttta agcgttacag aaggcaaaaa 4620  
acaagtagat gaaccctggt ttaatctctt attgcacgaa acgaaatttt caggagaaaa 4680  
gggtttaata gggcgtaata acgtcatgtt taccctctct ttagcctact ttagttcagg 4740  
ctattcaatc gaaacgtgcg aatataatat gtttgagttt aataatcgat tagatcaacc 4800  
cttagaagaa aaagaagtaa tcaaaaattgt tagaagtgcc tattcagaaa actatcaagg 4860

ggctaataagg gaatacatta ccattctttg caaagcttgg gtatcaagtg atttaaccag 4920  
taaagattta ttgtccgtc aagggtggtt taaattcaag aaaaaaagaa gcgaacgtca 4980  
acgtgttcat ttgtcagaat ggaaagaaga tttaatggct tatattagcg aaaaaagcga 5040  
tgtatacaag ccttatttag tgacgaccaa aaaagagatt agagaagtgc taggcattcc 5100  
tgaacggaca ttagataaat tgctgaaggc actgaaggcg aatcaggaaa ttttctttaa 5160  
gattaaacca ggaagaaatg gtggcattca acttgctagt gttaaatacat tgttgctatc 5220  
gatcattaaa gtaaaaaaag aagaaaaaga aagctatata aaggcgctga caaattcttt 5280  
tgacttagag catacattca ttcaagagac tttaaacaag ctagcagaac gccctaaaac 5340  
ggacacacaa ctcgatttgt ttagctatga tacaggctga aaataaaacc cgcactatgc 5400  
cattacattt atatctatga tacgtgtttg ttttttcttt gctgttttagc gaatgattag 5460  
cagaaatata cagagtaaga ttttaattaa ttattagggg gagaaggaga gagtagcccg 5520  
aaaactttta gttggcttgg actgaacgaa gtgagggaaa ggctactaaa acgtcgaggg 5580  
gcagtgagag cgaagcgaac acttgatttt ttaattttct atcttttata ggtcattaga 5640  
gtatacttat ttgtcctata aactatttag cagcataata gatttattga ataggtcatt 5700  
taagttgagc atattagagg aggaaaatct tggagaaata tttgaagaac ccgattacat 5760  
ggattggatt agttcttggt gttacgtggt ttttaactaa aagtagtgaa tttttgattt 5820  
ttggtgtgtg tgtcttggtg ttagtatttg ctagtcaaag tgattaaata 5870





## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>C07K 14/54, 14/715</b>	<b>A3</b>	<b>(11) International Publication Number:</b> <b>WO 00/23471</b> <b>(43) International Publication Date:</b> 27 April 2000 (27.04.00)
<b>(21) International Application Number:</b> PCT/EP99/07800 <b>(22) International Filing Date:</b> 6 October 1999 (06.10.99) <b>(30) Priority Data:</b> 98203529.7      20 October 1998 (20.10.98)      EP <b>(71) Applicant (for all designated States except US):</b> VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR BIOTECH- NOLOGIE VZW [BE/BE]; Rijvisschestraat 120, B-9052 Zwijnaarde (BE). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> STEIDLER, Lothar [BE/BE]; Bokslaarstraat 41, B-9160 Lokeren (BE). REMAUT, Erik, Rene [BE/BE]; Bergstraat 7, B-9921 Vinderhout (BE). FIERS, Walter [BE/BE]; Beukendreef 3, B-9070 Destelbergen (BE). <b>(74) Common Representative:</b> VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR BIOTECHNOLOGIE VZW; Rijviss- chestraat 120, B-9052 Zwijnaarde (BE).		<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>  <b>(88) Date of publication of the international search report:</b> 3 August 2000 (03.08.00)
<b>(54) Title:</b> USE OF A CYTOKINE-PRODUCING <i>LACTOCOCCUS</i> STRAIN TO TREAT COLITIS		
<b>(57) Abstract</b> <p>The current invention relates to an administraton strategy for the delivery at the intestinal mucosa of cytokines or cytokine antagonists, preferably of acid sensitive anti-inflammatory agents, such as IL10 and/or soluble TNF receptor via the oral route. The preferred feature according to the invention is the inoculation with a suspension of recombinant <i>Lactococcus lactis</i> cells, which had been engineered to produce the respective proteins.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

# INTERNATIONAL SEARCH REPORT

Int. Application No  
PCT/EP 99/07800

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 C07K14/54 C07K14/715

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 C07K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 11277 A (DOMPE SPA ;TAGLIABUE ALDO (IT); BORASCHI DIANA (IT); BOSSU PAOLA ( ) 18 April 1996 (1996-04-18) page 2, line 6 - line 11; claims 1-6,8 page 4, line 22 - line 27 page 6, line 29 -page 7, line 6 page 10, line 2 -page 11, line 20 page 11, line 28 -page 12, line 2 page 13, line 25 -page 15, line 2	1-6
A	WO 97 14806 A (UNIV CAMBRIDGE TECH ;STEIDLER LOTHAR (BE); REMAUT ERIK (BE); WELLS) 24 April 1997 (1997-04-24) cited in the application page 8, line 22 -page 9, line 6; claims 1,7,8,12,18 page 11, line 19 - line 25 page 12, line 23 -page 13, line 27 ----- -/-	1-5

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

20 April 2000

Date of mailing of the international search report

02/05/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Charles, D

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 99/07800

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>STEIDLER L ET AL: "Mucosal delivery of murine interleukin-2 (IL-2) and IL-6 by recombinant strains of Lactococcus lactis coexpressing antigen and cytokine."            INFECTION AND IMMUNITY, (1998 JUL) 66 (7) 3183-9. JOURNAL CODE: G07. ISSN: 0019-9567., XP002105819            United States            the whole document</p>	1,3,6



# INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. Application No

PCT/EP 99/07800

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9611277 A	18-04-1996	IT 1270123 B	28-04-1997
		AU 3745395 A	02-05-1996
		CA 2201721 A	18-04-1996
		EP 0784689 A	23-07-1997
		JP 10506791 T	07-07-1998
WO 9714806 A	24-04-1997	AU 7315496 A	07-05-1997
		BR 9610929 A	21-12-1999
		CN 1202934 A	23-12-1998
		EP 0871748 A	21-10-1998
		NO 981746 A	22-06-1998

